



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵: A61K 48/00, C07H 21/00, 21/04, C12Q 1/68</p>	A1	<p>(11) International Publication Number: WO 94/19023 (43) International Publication Date: 1 September 1994 (01.09.94)</p>
<p>(21) International Application Number: PCT/US93/01579 (22) International Filing Date: 19 February 1993 (19.02.93) (71) Applicant: ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US). (72) Inventors: COOK, Phillip, Dan; 7340 Bolero Street, Carlsbad, CA 92009 (US). BASCHANG, Gerhard; Buckenweg 7, CH-4126 Bettingen (CH). (74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place - 46th floor, Philadelphia, PA 19103 (US).</p>	<p>(31) Designated States: AU, BB, BG, BR, CA, CZ, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i></p>	
<p>(54) Title: CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF (57) Abstract Oligonucleotide surrogates comprising a plurality of cyclobutyl moieties covalently joined by linking moieties are prepared and used as antisense diagnostics, therapeutics and research reagents. Methods of synthesis and use of both the oligonucleotide surrogates and intermediates thereof are disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	KZ	Kazakhstan	SI	Slovenia
CM	Cameroon	LJ	Liechtenstein	SK	Slovakia
CN	China	LK	Sri Lanka	SN	Senegal
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
ES	Spain	MG	Madagascar	UA	Ukraine
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

"Cyclobutyl antisense oligonucleotides, methods of making and use thereof".

FIELD OF THE INVENTION

This application is directed to oligonucleotide surrogate compounds and their intermediates and to their design, synthesis and use. More particularly this invention is directed to oligonucleotide surrogate compounds that include linked cyclobutyl rings having heterocyclic bases attached thereto. Such oligonucleotide surrogates are useful for therapeutics, diagnostics and as research reagents.

BACKGROUND OF THE INVENTION

It is well known that most of the bodily states in mammals including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man. Classical therapeutics has generally focused upon interactions with such proteins in an effort to moderate their disease causing or disease potentiating functions. Recently, however, attempts have been made to moderate the actual production of such proteins by interactions with messenger RNA (mRNA) or other intracellular RNA's that direct protein synthesis. It is the generally object of such therapeutic approaches to interfere with or otherwise

modulate gene expression leading to undesired protein formation.

Antisense methodology is the complementary hybridization of relatively short oligonucleotides to single-stranded RNA or single-stranded DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted. Hybridization is the sequence specific hydrogen bonding via Watson-Crick base pairs of the heterocyclic bases of oligonucleotides to RNA or DNA. Such base pairs are said to be complementary to one another.

Naturally-occurring events that provide for the disruption of the nucleic acid function, as discussed by Cohen in *Oligonucleotides: Antisense Inhibitors of Gene Expression*, CRC Press, Inc., Boca Raton, Fl (1989), are thought to be of two types. The first is hybridization arrest. This denotes the terminating event in which an oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides: Miller, P.S. and Ts' O, P.O.P. (1987) *Anti-Cancer Drug Design*, 2:117-128, and α -anomer oligonucleotides are the two most extensively studied antisense agents that are thought to disrupt nucleic acid function by hybridization arrest.

In determining the extent of hybridization arrest of an oligonucleotide, the relative ability of an oligonucleotide to bind to complementary nucleic acids may be compared by determining the melting temperature of a particular hybridization complex. The melting temperature (T_m), a characteristic physical property of double helixes, denotes the temperature in degrees centigrade at which 50% helical versus coil (unhybridized) forms are

present. T_m is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher T_m . The higher the T_m , the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the T_m .

10 The second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H. A 2'-deoxyribofuranosyl oligonucleotide hybridizes with the targeted RNA and this duplex activates the RNase H enzyme to cleave the
15 RNA strand, thus destroying the normal function of the RNA. Phosphorothioate oligonucleotides are the most prominent example of an antisense agent that operates by this type of antisense terminating event.

Considerable research is being directed to the
20 application of oligonucleotides as antisense agents for diagnostics, research reagents and potential therapeutic purposes. This research has included the synthesis of oligonucleotides having various modification. Such modification have primarily been modifications of the
25 phosphate links that connect the individual nucleosides of the oligonucleotide. Various phosphorothioates, phosphotriesters, phosphoramidates and alkyl phosphonates have been reported. Further research has been directed to replacement of the inter-nucleoside phosphates with
30 other moieties such as carbamates, sulfonates, siloxanes and the formacetal group. Other modification have been effected wherein conjugate groups are attached to the nucleosides of the oligonucleotide via linking groups. Such conjugates include fluorescent dyes, intercalating

- 4 -

agents, proteins, cross-linking agents, chain-cleaving agents and other groups including biotin and cholesterol. An extensive review discussing all of these modifications is that of Goodchild, J. (1990) *Bioconjugate Chemistry*,
5 1:165.

Since the heterocyclic bases of the nucleosides of an antisense oligonucleotide are necessary for the proper Watson/Crick binding of the antisense oligonucleotide to the target RNA or DNA, with the exception of cross-
10 linking agents, little has been reported as to modification on the heterocyclic bases.

"Alpha" nucleosides have been used to form oligonucleotides having "alpha" sugars incorporated therein. In a like manner 2'-O-methylribonucleotides also have been used
15 as precursor building blocks for oligonucleotides. United States Patent No. 5,034,506 and PCT Patent Application PCT/US86/00544 suggest that the sugar portion of a nucleoside can be ring opened via oxidization and then ring closed by reactions with an amino or hydrazine group
20 on an adjacent nucleoside. This links the nucleosides. Further, upon ring closure with the amino or hydrazine group, a new ring, a morphine ring, is formed from the residue of the oxidized pentofuranose sugar ring of the nucleoside. PCT/US86/00544 also suggests that a linear
25 amino acid based polymer might be used in place of a sugar-phosphate backbone to link heterocyclic bases together in an oligonucleotide-like linkage. Aside from these modifications, modification of the sugar moieties of the nucleosides of oligonucleotides is also little
30 known.

In a further approach to modification of oligonucleotides both the sugar moieties and the phosphates linker have been removed and replaced by a polymeric backbone. Utilizing this approach, heterocyclic bases have been
35 tethered to various polymers including poly(N-vinyl),

GP 055934

SUBSTITUTE SHEET

- 5 -

poly(methacryloxyethyl), poly(methacrylamide), poly(ethyleneimine) and poly(lysine). These types of compounds generally suffer from inappropriate spatial orientation of the heterocyclic bases for proper hybridization with a target RNA or DNA. A review of such polymeric compounds and the before noted "alpha" sugar containing oligonucleotides and 2'-O-methylribonucleotides is found in Uhlmann, E. and Peyman, A., (1990) *Chemical Reviews*, 90:543.

Recently oxetanocin and certain of its carbocyclic analogs have been studied as antiviral chemotherapeutic agents. These compounds incorporate an oxetane or a cyclobutane ring in place of the sugar moiety of a nucleoside. Cyclobut-A, i.e. (\pm)-9-[(1 β ,2 α ,3 β)-2,3-bis(hydroxymethyl)-1-cyclobutyl]adenine, and cyclobut-G, i.e. (\pm)-9-[(1 β ,2 α ,3 β)-2,3-bis(hydroxymethyl)-1-cyclobutyl]guanine, were reported by Norbeck, D.W., Kern, E. Hayashi, S., Rosenbrook, W., Sham, H., Herrin, T., Plattner, J.J., Erickson, J., Clement, J., Swanson, R., Shipkowitz, N., Hardy, D., Marsh, K., Arnett, G., Shannon, W., Broder, S. and Mitsuya, H. (1990) *J. Med. Chem.*, 33:1281. Further antiviral activity of these compounds was reported by Hayashi, S., Norbeck, D.W., Rosenbrook, W., Fine, R.L., Matsukura, M., Plattner, J.J., Broder, S. and Mitsuya, H. (1990) *Antimicrobial Agents and Chemotherapy*, 34:287. As reported in Hayashi et. al., both cyclobut-A and cyclobut-G exist as racemic mixtures of diastereomers. Also as reported by Hayashi et. al., the thymine, uracil and hypoxanthine analogs of cyclobut-A and cyclobut-G did not exhibit antiviral activity.

In an attempt to eliminate any effects that the racemic, diastereomeric 2,3-bis(hydroxymethyl)-1-cyclobutyl portion of cyclobut-A and cyclobut-G might have towards phosphorylation by kinases, non-diastereomeric 3,3-bis(hydroxymethyl)-1-cyclobutyl analogs of cyclobut-A and cyclobut-G were synthesized and reported by Boumchita, H.,

Legraverenc, M., Huel, C. and Bisagni, E. (1990) *J. Heterocyclic Chem.* 27:1815.. However, contrary to the activity of cyclobut-A and cyclobut-G, the 3,3-bis(hydroxymethyl)-1-cyclobutyl analogs of adenine and guanine, i.e. 9-[3,3-bis(hydroxymethyl)cyclobut-1-yl]adenine and 9-[3,3-bis(hydroxymethyl)cyclobut-1-yl]guanine, respectively, were found to be devoid of antiviral activity.

OBJECTS OF THE INVENTION:

10 It is one object of this invention to provide oligonucleotide surrogate compounds that incorporate cyclobutyl moieties.

It is a further object to provide cyclobutyl-based oligonucleotides surrogate compounds that have antisense hybridizability against DNA and RNA sequences.

15 It is another object of this invention to provide cyclobutyl-based oligonucleotide surrogate compounds for use in antisense diagnostics and therapeutics.

A still further object is to provide research and diagnostic methods and materials for assaying bodily states in animals, especially diseased states.

Another object is to provide therapeutic and research methods and materials for the treatment of diseases through modulation of the activity of DNA and RNA.

25 It is yet another object to provide methods for synthesizing sequence-specific cyclobutyl-based oligonucleotide surrogate compounds.

These and other objects will become apparent to the art skilled from a review of this specification and the claims appended hereto.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with this invention there are provided oligonucleotide surrogates that are formed from a plurality of cyclobutyl moieties that are covalently joined


by linking moieties; each of the cyclobutyl moieties has one of a purine or a pyrimidine heterocyclic base attached to it.

In preferred oligonucleotide surrogates of the invention the purine or pyrimidine heterocyclic base is a naturally-occurring or synthetic purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl heterocyclic base. Preferably, the purine or pyrimidine heterocyclic base is adenine, guanine, cytosine, thymidine, uracil, 5-methylcytosine, hypoxanthine or 2-aminoadenine.

In preferred oligonucleotide surrogates the heterocyclic base is attached to each respective cyclobutyl moiety at the carbon-1 (C-1) position of said cyclobutyl moiety and the linking moieties connect to each respective cyclobutyl moiety at the carbon-3 (C-3) position thereof. In these preferred embodiments, a substituent group can be located on one of the carbon-2 (C-2) or the carbon-4 (C-4) positions of at least one of the cyclobutyl moieties. Preferred substituents include halogen, C₁-C₁₀ alkoxy, allyloxy, C₁-C₁₀ alkyl or C₁-C₁₀ alkylamine groups. Preferably, the substituent group is positioned *trans* to the heterocyclic base.

In preferred oligonucleotide surrogates of the invention, the linking moieties are 4 or 5 atoms chains that connect adjacent cyclobutyl moieties. When the linking moieties are 5 atoms chains, each of the linking moieties preferably is of the structure L₁-L₂-L₃, where L₁ and L₃ are CH₂; and L₂ is phosphodiester, phosphorothioate, phosphoramidate, phosphotriester, C₁-C₆ alkyl phosphonate, phosphorodithioate, phosphonate, carbamate, sulfonate, C₁-C₆-dialkylsilyl or formacetal. Preferably, each of the linking moieties is of the structure L₁-L₂-L₃, where L₁ and L₃ are CH₂ and L₂ is phosphodiester or phosphorothioate.

When the linking moieties are 4 atom chains, each of the linking moieties preferably is of the structure:



where:

- 5 (a) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , independently, are CR_1R_2 , $C=CR_1R_2$,
 $C=NR_3$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_4R_5 ;
or
(b) L_4 and L_7 are CH_2 ; and
10 L_5 and L_6 , together, are $CR_1=CR_2$, $C\equiv C$, part of
a C_6 aromatic ring, part of a C_3-C_6 carbocyclic
ring or part of a 3, 4, 5 or 6 membered hetero-
cyclic ring; or
(c) $L_4-L_5-L_6-L_7$, together, are $CH=N-NH-CH_2$ or CH_2-
15 $O-N=CH$;

wherein:

R_1 and R_2 , independently, are H, OH, SH, NH_2 ,
 C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_1-C_{10}
alkenyl, C_7-C_{10} aralkyl, C_1-C_6 alkoxy, C_1-C_6 thio-
20 alkoxy, C_1-C_6 alkylamino, C_7-C_{10} aralkylamino, C_1-
 C_{10} substituted alkylamino, heterocycloalkyl, hetero-
cycloalkylamino, aminoalkylamino, polyalkylamino,
halo, formyl, keto, benzoxy, carboxamido, thiocarbox-
amido, ester, thioester, carboxamidino, carbamyl,
25 ureido, guanidino, an RNA cleaving group, a group
for improving the pharmacokinetic properties of an
oligonucleotide, or a group for improving the
pharmacodynamic properties of an oligonucleotide;

R_3 is H, OH, NH_2 , C_1-C_6 alkyl, substituted lower
30 alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino,
aralkylamino, substituted alkylamino, heterocyclo-
alkyl, heterocycloalkylamino, aminoalkylamino,
polyalkylamino, a RNA cleaving group, a group for
improving the pharmacokinetic properties of an oligo-

- 9 -

nucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; and

R_4 and R_5 , independently, are C_1 - C_6 alkyl or alkoxy.

- 5 Particularly preferred 4 atom linking moieties are $CH=N-NH-CH_2$, $CH_2-NH-NH-CH_2$, $CH_2-O-NH-CH_2$ or $CH_2-O-N=CH$.

Further in accordance with this invention there is provided a method for modulating the production or activity of a protein in an organism, comprising contact-
10 ing the organism with an oligonucleotide surrogate formulated in accordance with the forgoing considerations. Such an oligonucleotide surrogate is specifically hybridizable with at least a portion of a nucleic acid sequence, i.e. an RNA or DNA, coding for the protein. At least a
15 portion of the oligonucleotide surrogate is formed from a plurality of linked cyclobutyl moieties, each moiety having an attached purine or pyrimidine heterocyclic base.

Additionally in accordance with this invention there is provided a method of treating an organism having a
20 disease characterized by the undesired production of a protein. This method includes contacting the organism with an oligonucleotide surrogate also formulated in accordance with foregoing considerations. Such an oligonucleotide surrogate is specifically hybridizable
25 with at least a portion of a nucleic acid sequence, i.e. an RNA or DNA sequence, coding for the protein whose production or activity is to be modulated. At least a portion of the oligonucleotide surrogate is formed from a plurality of linked cyclobutyl moieties, wherein each
30 moiety having an attached purine or pyrimidine heterocyclic base.

Further in accordance with this invention there is provided a pharmaceutical composition containing as its active ingredient an effective amount of an oligonucleo-

GP 055939

tide surrogate formed from a plurality of linked cyclobutyl moieties, each moiety having an attached purine or pyrimidine heterocyclic base; and a pharmaceutically acceptable diluent or carrier.


5 Even further in accordance with this invention there is provided a method of in vitro assaying a sequence specific nucleic acid, i.e. an RNA or DNA, comprising contacting an in vitro composition which includes the nucleic acid with an oligonucleotide surrogate that is
10 specifically hybridizable with at least a portion of the nucleic acid. The oligonucleotide surrogate preferably is formulated in accordance with the foregoing considerations. Thus, at least a portion of the oligonucleotide surrogate compound is formed from a plurality of linked
15 cyclobutyl moieties, each moiety having an attached purine or pyrimidine heterocyclic base.

Even further in accordance with this invention there is provided a process for the preparation of a compound formed from a plurality of linked cyclobutyl moieties
20 wherein each moiety has an attached purine or pyrimidine heterocyclic base. The process comprises the steps of: functionalizing the cyclobutyl moieties with a leaving group; displacing the leaving group on each of the cyclobutyl moieties with an independently selected purine or
25 pyrimidine heterocyclic base; functionalizing each of the base-containing cyclobutyl moieties with a protecting group; further functionalizing the protected moieties with an activated linking group; and stepwise deprotecting and linking the heterocyclic-base-containing cyclobutyl
30 moieties. Such processes can be augmented to include stepwise deprotection and linkage of the base-containing cyclobutyl moieties on a polymeric support. In a preferred embodiment of this process, the base-containing cyclobutyl moieties are stepwise deprotected and linked
35 together by: (a) deprotecting a first of the protected

- 11 -

moieties; (b) linking a further of the protected moieties bearing an activated linking group with the deprotected moiety to form a linked structure; and (c) deprotecting the linked structure. Deprotecting and linking steps (b) and (c) preferably are repeated a plurality of times.

Even further in accordance with this invention there is provided an antiviral composition containing as its active ingredient an effect amount of a compound of structure (A):



10

STRUCTURE (A)

wherein B_x is purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl; and a pharmaceutically acceptable diluent or carrier.

Additionally in accordance with this invention there is provided a method of treating viral diseases in mammals comprising administering to the mammal a therapeutic amount of a composition containing as its active ingredient a compound of the structure (A). In preferred embodiments, the viral disease is a herpes viral disease.

DETAILED DESCRIPTION OF THE INVENTION

20

In the context of this invention, the term "nucleoside" refers to a molecular species made up of a heterocyclic base and a sugar. In naturally-occurring nucleosides, the heterocyclic base typically is guanine, adenine, cytosine, thymine, or uracil. Other natural bases are known, as are a plenitude of synthetic or "modified" bases. In naturally-occurring nucleosides, the sugar is normally deoxyribose (DNA type nucleosides) or ribose (RNA type nucleosides). Synthetic sugars also are

GP 055941

- 12 -

known, including arabino, xylo or lyxo pentofuranosyl sugars and hexose sugars. Historically, the term nucleoside has been used to refer to both naturally-occurring and synthetic species formed from naturally-occurring or
5 synthetic heterocyclic base and sugar subunits.

The term "nucleotide" refers to a nucleoside having a phosphate group esterified to one of its 2', 3' or 5' sugar hydroxyl groups. The phosphate group normally is a monophosphate, a diphosphate or triphosphate. The term
10 "oligonucleotide" normally refers to a plurality of joined monophosphate nucleotide units. These units are formed from naturally-occurring bases and pentofuranosyl sugars joined by native phosphodiester bonds. A homo-oligonucleotide is formed from nucleotide units having a common
15 heterocyclic base.

The term "oligonucleotide analog" has been used to refer to molecular species which are structurally similar to oligonucleotides but which have non-naturally-occurring portions. This term has been used to identify oligo-
20 nucleotide-like molecules that have altered sugar moieties, altered base moieties, or altered inter-sugar linkages. Thus, the term oligonucleotide analog denotes structures having altered inter-sugar linkages such as phosphorothioate, methyl phosphonate, phosphotriester or
25 phosphoramidate inter-nucleoside linkages in place of native phosphodiester inter-nucleoside linkages; purine and pyrimidine heterocyclic bases other than guanine, adenine, cytosine, thymine or uracil; carbocyclic or acyclic sugars; sugars having other than the β pentofuranosyl configuration; or sugars having substituent
30 groups at their 2' position or at one or more of the sugar hydrogen atoms.

Certain oligonucleotide analogs having non-phosphodiester bonds, i.e. an altered inter-sugar linkage, can be
35 referred to as "oligonucleosides." The term oligonucleo-

GP 055942

SUBSTITUTE SHEET

- 13 -

side thus refers to a plurality of joined nucleoside units joined by linking groups other than native phosphodiester linking groups. Additionally, the term "oligomers" can be used to encompass oligonucleotides and oligonucleotide
5 analogs. Generally, the inter-sugar linkages of oligonucleotides and oligonucleotide analogs are from the 3' carbon of one nucleoside to the 5' carbon of a second nucleoside; however, the terms oligomer and oligonucleotide analog also have been used in reference to 2'-
10 5' linked oligonucleotides.

Antisense therapy is the use of oligonucleotides or oligonucleotide analogs to bind with complementary strands of RNA or DNA. After binding, the oligonucleotide and the RNA or DNA strand are "duplexed" together in a manner
15 analogous to native, double-stranded DNA. The oligonucleotide strand and the RNA or DNA strand can be considered complementary strands wherein the individual strands are positioned with respect to one another to allow Watson/Crick type hybridization of the heterocyclic
20 bases of one strand to the heterocyclic bases of the opposing strand.

Antisense therapeutics can be practiced in a plethora of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.
25 Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to antisense therapeutics and/or prophylactics. Seemingly diverse organisms such as bacteria, yeast, protozoa,
30 algae, and all plant and all higher animal forms, including warm-blooded animals, can be treated by antisense therapy. Further, since each of the cells of multicellular eukaryotes includes both DNA-RNA transcription and RNA-protein translation as an integral part of their
35 cellular activity, antisense therapeutics and/or diagnos-

tics can also be practiced on such cellular populations. Furthermore, many of the organelles, e.g. mitochondria and chloroplasts, of eukaryotic cells also include transcription and translation mechanisms. As such, single cells, 5 cellular populations and organelles can also be included within the definition of organisms that are capable of being treated with antisense therapeutics or diagnostics. As used herein, therapeutics is meant to include both the eradication of a disease state, killing of an organism, 10 e.g. bacterial, protozoan or other infection, or control of erratic or harmful cellular growth or expression.

Antisense therapy utilizing "oligonucleotide analogs" is exemplified in the disclosures of the following United States and PCT Patent Applications: Serial No. 463,358, 15 filed January 11, 1990, entitled Compositions And Methods For Detecting And Modulating RNA Activity; Serial No. 566,836, filed August 13, 1990, entitled Novel Nucleoside Analogs; Serial No. 566,977, filed August 13, 1990, entitled Sugar Modified Oligonucleotides That Detect And 20 Modulate Gene Expression; Serial No. 558,663, filed July 27, 1990, entitled Novel Polyamine Conjugated Oligonucleotides; Serial No. 558,806, filed July 27, 1991, entitled Nuclease Resistant Pyrimidine Modified Oligonucleotides That Detect And Modulate Gene Expression; Serial 25 No. 703,619, filed May 21, 1991, entitled Backbone Modified Oligonucleotide Analogs; Serial No. PCT/US91/00243, filed January 11, 1991, entitled Compositions and Methods For Detecting And Modulating RNA Activity; and Serial No. PCT/US91/01822, filed March 19, 30 1991, entitled Reagents and Methods For Modulating Gene Expression Through RNA Mimicry. The foregoing applications are assigned to the assignee of this invention. The disclosure of each is incorporated herein by reference.

This invention is directed to certain molecular 35 species which are related to oligonucleotides but which

do not included a sugar moiety. In this invention, cyclobutane rings, i.e. cyclobutyl moieties, having heterocyclic bases attached thereto are connected by linking moieties into oligonucleotide-like structures.

5 Such structures, while chemically different from oligonucleotides (or oligonucleotide analogs), are functionally similar. Such molecular species are therefore oligonucleotide surrogates. As oligonucleotide surrogates they serve as substitutes for oligonucleotides. We have found

10 that they are capable of hydrogen bonding to complementary strands of DNA or RNA in the same manner as are oligonucleotides.

As will be recognized, a cyclobutane ring system may be considered as fixed when compared to a pentofuranose

15 ring system. Thus, while a pentofuranose ring system allows for rotation about intra-ring chemical bonds, a cyclobutane ring system does not. Consequently, the pentofuranosyl ring system can "pucker"; a cyclobutane ring cannot. However, like a pentofuranosyl ring, a

20 cyclobutane ring system has a sufficient number of functional positions within the ring to allow for placement of a number of substituent functional groups.


The nomenclature of nucleoside chemistry utilizes unprimed numbers to identify the functional positions on the

25 heterocyclic base portion of the nucleoside and primed numbers to identify the functional positions on the sugar portion of the nucleoside. Further, the β isomer of a ribofuranosyl ring is syn about the anomeric C-1 position is syn with respect to the C-5 carbon, while the α isomer

30 is trans with respect to the C-5 carbon. IUPAC recommended nomenclature for the functional positions of cyclobutane differ from such standard nucleoside nomenclature. Utilizing IUPAC nomenclature, the substitution of position C-1 in the cyclobutane ring is always α .

- 16 -

For the purposes of this invention, positional identification of the cyclobutane ring is made by reference to structure (B):



STRUCTURE (B)

5 In the illustrative example below and the claims appended hereto, positional nomenclature is determined in a manner consistent with structure (B).

The oligonucleotide surrogates of the invention are formed by linking together a plurality of cyclobutyl moieties via linking moieties. Each of the cyclobutyl moieties includes a covalently-bound purine or pyrimidine heterocyclic base. Each of the linking moieties covalently bond two adjacent cyclobutyl moieties. Linked together in this manner, the cyclobutyl moieties present their heterocyclic bases in spatial positions for hybridization with DNA or RNA strands.

According to the present invention, cyclobutyl-based oligonucleotide surrogates include a plurality of subunits. Each subunit includes a cyclobutane ring, a heterocyclic base, and a linking moiety for joining adjacent subunits. The oligonucleotide surrogates of the invention preferably comprise from about 3 to about 100 subunits. Preferably, oligonucleotide surrogates comprise greater than about 6 subunits, preferably from about 8 to about 60 subunits, even more preferably from about 10 to about 30 subunits.

The heterocyclic base of each of the subunits can be a natural heterocyclic base or a synthetic heterocyclic base. In preferred embodiments the heterocyclic base is

- 17 -

selected as a naturally-occurring or synthetic purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl heterocyclic base. Heterocyclic bases include but are not limited to adenine, guanine, cytosine, thymidine, uracil, 5-methylcytosine, hypoxanthine or 2-aminoadenine. Other such heterocyclic bases include 2-aminopurine, 2,6-diaminopurine, 6-mercaptopurine, 2,6-dimercaptopurine, 3-deazapurine, 6-amino-3-deazapurine, 6-amino-3-deaza-2-oxypurine, 2-amino-6-mercaptopurine, 5-methylcytosine, 4-amino-2-mercapto-
10 pyrimidine, 2,4-dimercaptopyrimidine, 5-fluorocytosine.

Other suitable heterocyclic bases include those identified in Patent Application Serial No. 558,806, filed July 27, 1990, entitled Nuclease Resistant Pyrimidine Modified Oligonucleotides That Detect and Modulate Gene
15 Expression and in PCT Patent Application US6/00544. The portions of these patent applications that set forth such heterocyclic bases are incorporated herein by reference.

In accordance with the invention, linking moieties are selected to covalently link individual heterocyclic-
20 base-containing cyclobutyl moieties together in an orientation wherein the heterocyclic bases are positioned in space in a conformation which allows hybridization with a complementary strand of DNA or RNA.

In preferred embodiments of the invention the linking
25 moieties are selected as 4 or 5 atoms chains. Such 4 and 5 atoms chains include the phosphodiester linkages of native DNA and RNA as well as the related synthetic phosphorothioate, phosphoramidate, alkyl phosphonate, phosphorodithioate and phosphotriester linkages of "oligo-
30 nucleotide analogs." Other linking moieties include phosphate, carbamate, sulfonate, C₁-C₆-dialkylsilyl or formacetal linkages. Further linkages include an -O-CH₂-CH₂-O- linkage and the novel linkages disclosed in United

States Patent Applications Serial No. 566,835 and Serial No. 703,619, identified above.

A preferred group of 5 atom linking moieties of the invention include linking moieties of the structure L_1 - L_2 - L_3 where L_1 and L_3 are CH_2 ; and L_2 is phosphodiester, phosphorothioate, phosphoramidate, phosphotriester, C_1 - C_6 alkyl phosphonate, phosphorodithioate, phosphonate, carbamate, sulfonate, C_1 - C_6 -dialkylsilyl or formacetal. A particularly preferred group of such 5 atom linker is of the structure L_1 - L_2 - L_3 where L_1 and L_3 are CH_2 ; and L_2 is phosphodiester or phosphorothioate.

A preferred group of 4 atoms linking moieties of the invention include linking moieties of the structure L_4 - L_5 - L_6 - L_7 where:

L_4 and L_7 are CH_2 ; and L_5 and L_6 , independently, are CR_1R_2 , $C=CR_1R_2$, $C=NR_3$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_4R_5 ; or

L_5 and L_6 , together, are $CR_1=CR_2$, $C\equiv C$, part of a C_6 aromatic ring, part of a C_3 - C_6 carbocyclic ring or part of a 3, 4, 5 or 6 membered heterocyclic ring; or

L_4 - L_5 - L_6 - L_7 , together, are $CH=N-NH-CH_2$ or $CH_2-O-N=CH$;

wherein:

R_1 and R_2 , independently, are H, OH, SH, NH_2 , C_1 - C_{10} alkyl, C_1 - C_{10} substituted alkyl, C_1 - C_{10} alkenyl, C_7 - C_{10} aralkyl, C_1 - C_6 alkoxy, C_1 - C_6 thioalkoxy, C_1 - C_6 alkylamino, C_7 - C_{10} aralkylamino, C_1 - C_{10} substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, halo, formyl, keto, benzoxy, carboxamido, thiocarboxamido, ester, thioester, carboxamidino, carbamyl, ureido, guanidino, an RNA cleaving group, a group for

improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide;


5 R_3 is H, OH, NH_2 , C_1-C_6 alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, a RNA cleaving group, a group for
10 improving the pharmacokinetic properties of an oligonucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; and

R_4 and R_5 , independently, are C_1-C_6 alkyl or alkoxy.

Groups that enhance pharmacodynamic properties
15 improve uptake of the oligonucleotide surrogates, enhance the resistance of the oligonucleotide surrogates to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance pharmacokinetic properties improve the uptake, distribution, metabolism
20 or excretion of the oligonucleotide surrogates. A particularly preferred group of 4 atom linking moieties includes $CH=N-NH-CH_2$, $CH_2-NH-NH-CH_2$, $CH_2-O-NH-CH_2$ and $CH_2-O-N=CH$.

In addition to heterocyclic bases and linking moieties, the cyclobutyl moieties of the invention can
25 further include other substituent groups. For oligonucleotide surrogates of the invention having their heterocyclic base at position C-1 and the linking moieties at position C-3, such substituent groups can be located on one or both of the C-2 or the C-4 position. Preferred
30 substituent groups include halogen, C_1-C_{10} alkoxy, allyloxy, C_1-C_{10} alkyl or C_1-C_{10} alkylamine. Preferably the substituent group is positioned trans to said heterocyclic base.

Certain preferred embodiments of the invention take advantage of the symmetry of 3,3-bis-hydroxymethyl-cyclobutane substituted at the C-1 position with a heterocyclic base, as in structure (C).



5

STRUCTURE (C)

Compounds of this type can be synthesized by procedures which involve first preparing 1-heterocyclic, base-substituted derivatives of 1-benzyloxy-3,3-bis-hydroxymethyl-cyclobutane. These base-bearing compounds are then
10 directly converted to their corresponding mono-O-substituted methoxytrityl derivatives. In one embodiment of the invention, the mono-O-substituted methoxytrityl derivatives are then converted to octameric phosphodiester on an aminomethyl-polystyrene carrier utilizing the phospho-
15 triester method of Van Boom, J.H., Van der Marel, G.A., Van Boeckel, C.A.A., Wille, G. and Hoyng, C. *Chemical and Enzymatic Synthesis of Gene Fragments*, A Laboratory Manual, edited by H.G. Gassen and Anne Lang, Verlag Chemie Weinheim/Deerfield Beach, Florida/Basel 1982.

20

Utilizing 1-benzyloxy-3,3-bis-hydroxymethyl-cyclobutane, 1-thymidyl-3,3-bis-hydroxymethyl-cyclobutane and 1-adenyl-3,3-bis-hydroxymethyl-cyclobutane can be synthesized by direct introduction of the heterocyclic bases; uridyl-3,3-bis-hydroxymethyl-cyclobutane, 1-guanyl-3,3-
25 bis-hydroxymethyl-cyclobutane and 1-cytidyl-3,3-bis-hydroxymethyl-cyclobutane are prepared by similar procedures, as are cyclobutanes substituted with other heterocyclic bases. To effect direct introduction of the heterocyclic base, the known 1-benzyloxy-3,3-bis-hydroxymethyl-cyclobutane is converted to the O⁵,O^{5'}-isopropyl-

30

dene-ether of 1-hydroxy-2,3-bis-hydroxymethyl-cyclobutane. Various sulfonate esters were examined for the introduction of the heterocyclic base. In the series mesylate, tosylate, brosylate and nosylate, the best properties with respect to stability and reaction conditions for substitution were observed with the *p*-bromobenzenesulfonate.


Introduction of adenine was accomplished in 90 % yield in DMSO at 80° C for 24 hours. Only the N⁹-substituted product was detected by TLC. Substitution with 3 equivalents of thymine under the same conditions led to a mixture of 3 products: N¹-substituted (55 %), disubstituted (34 %) and traces of N³-substituted product. Use of a four-fold excess of thymine did not suppress the formation of the disubstituted product. The desired heterocyclic-base-substituted compounds were purified by flash chromatography and were deprotected with hydrochloric acid in dioxane to yield corresponding 3,3-bis hydroxymethyl derivatives having an appropriate heterocyclic base at the C-1 position.

Reaction of the 1-heterocyclic-base-substituted 3,3-bis-hydroxymethyl-cyclobutanes with monomethoxytrityl chloride yielded the desired monomethoxytrityl derivatives. After separation of the isomers, these compounds can then directly be used to form oligonucleotide surrogates via phosphotriester oligonucleotide synthesis methods. Alternately, they may be converted to a corresponding phosphoramidate for use in the phosphoramidate oligonucleotide synthesis method.


Utilizing phosphotriester chemistry, reaction of 3,3-bis-hydroxymethyl-1-thymidyl-cyclobutane with 1.3 equivalents of monomethoxytrityl chloride in pyridine led to two monosubstituted products (35 % and 42 % yields, respectively) as well as the disubstituted derivative (9 %) and unreacted starting material (6.5 %). Addition of

more methoxytrityl chloride did not diminish the amount of starting diol, but rather increased the amount of disubstituted product. The two mono-substituted isomers were each independently processed by the phosphotriester method to octameric phosphodiester on a solid support with thymidine as a starting nucleoside.

Because of the asymmetry of the starting isomers, the resulting oligonucleotide surrogate compounds were of a pseudo- β - and a pseudo- α -configuration. The designation "pseudo- β " refers to an oligonucleotide surrogate of the invention formed from cyclobutane units having their heterocyclic base positioned *cis* to what would be the 5' position of a natural oligonucleotide; "pseudo- α " refers to oligonucleotide surrogates where the heterocyclic base would be *trans* to that same 5' position. The pseudo- α and pseudo- β configurations are shown in structures (D) and (E). A "normal" terminal thymidine nucleotide has been included in the structures at the "3'" terminal ends to better illustrate the configurations of the cyclobutane based oligonucleotide surrogates of the invention.



STRUCTURE (D)
PSEUDO- α



STRUCTURE (E)
PSEUDO- β

In the adenine series (and in like manner in the guanine and cytosine series) the amino group of a 1-5 (heterocyclic base)-3,3-bis-hydroxymethyl-cyclobutane is first protected by benzylation to provide the N,N-dibenzoate derivative in 95 % yield. This dibenzoate compound is then further converted to the desired isomers of N⁶-benzoyl-O⁵-methoxytrityl-3-hydroxymethyl-1-adenyl-

10 cyclobutane in two different ways. Removal of the isopropylidene group prior to mono-debenzylation with ammonia in THF proved to be more efficient compared to mono-debenzylation prior to removal of the isopropylidene group. Following mono-debenzylation and removal of the

15 isopropylidene group, the resulting isomers of the alcohols were again separately processed to octameric phosphodiester on a solid support with 2-deoxy-adenosine as a starting nucleoside. This gave the desired pseudo- β - and pseudo- α -oligonucleotide surrogates.

20 As a further aspect of this invention the *cis* and *trans* isomers of mono-hydroxymethyl substituted adenylicyclobutane were also prepared. A chromatographic

separation of the *cis* and *trans* isomers of carboethoxy intermediates was utilized. The procedure was applied separately to both isomers of 1-benzyloxy-3-carboethoxy-cyclobutane. Reduction of the carboethoxy group with
5 lithium aluminum hydride, protection with *t*-butyldiphenylsilyl chloride, hydrogenolytic removal of the benzyl group, introduction of the leaving group with *p*-bromobenzenesulfonylchloride, and substitution with adenine in the presence of DBU in DMSO led to *t*-butyl-diphenylsilyl
10 protected N⁹-substituted adenine derivatives, together with the corresponding N⁷-substituted derivatives. In both cases desired compounds were separated by chromatography. Final deprotection with hydrofluoric acid in urea gave the desired *cis* and *trans* 1-adenyl-3-hydroxy-
15 methyl-cyclobutanes.

For the introduction of N⁴-isobutyryl-cytosine and 2-amino-6-methoxyethoxy-purine (the corresponding guanine compound) the phenylsulfonyl leaving group proved to be the most efficient.

20 Syntheses of 1-adenyl-3,3-bis-hydroxymethyl-cyclobutane were recently reported by Maruyama, T., Sato, Y., Horii, T., Shiota, H., Nitta, K., Shirasaka, T., Mitsuya, H. and Honjo, J. (1990) *J. Chem. Pharm. Bull.*, 38:2719 and
25 Boumchita, H., Legraverend, M., Huel, C. and Bisagni, E. (1990) *J. Heterocyclic Chem.*, 27:1815. Both of these groups made use of a 1-amino derivative that was then elaborated to the end products by a stepwise synthesis of the heterocycle. This is to be contrasted with the teachings of this invention, wherein the heterocyclic
30 bases are introduced directly by exploiting the preferential alkylation of these bases.

For the preparation of oligonucleotide surrogate compounds of the invention having phosphorothioate, phosphoramidate, phosphotriester, C₁-C₆ alkyl phosphonate

and phosphorodithioate groups, the oligonucleotide synthetic methods based on phosphoramidate chemistry of the following, above-referenced United States and PCT Patent Applications: Serial No. 566,836, Serial No. 5 463,358, Serial No. 558,806, Serial No. 558,663, Serial No. 566,977 and Serial No. US91/00243. Briefly, protected 1-adenyl, guanyl or cytidyl or unprotected thymidyl and uridyl-3-monomethoxytrityl-3-hydroxymethyl-cyclobutane are phosphitylated and the resulting activated phosphate 10 monomers are then joined to appropriate oligonucleotide surrogates. A phosphorothioate-type backbone is formed utilizing the Beaucage reagent, i.e. 3H-1,2-benzodithioate-3-one 1,1-dioxide, see Radhakrishnan, P.I., Egan, W., Regan, J.B. and Beaucage, S.L., (1990), *J. Am. Chem. Soc.*, 112:1253. 15

For the preparation of oligonucleotide surrogate compounds of the invention having 4 atom linking moieties, the synthetic methods of United States Patent Applications Serial No. 566,836 and Serial No. 703,619 are practiced. 20 Specifically, the 3-hydroxymethyl group of a protected 1-adenyl, guanyl or cytidyl or unprotected thymidyl and uridyl-3-monomethoxytrityl-3-hydroxymethyl-cyclobutane is oxidized to the corresponding 3-aldehydic derivative by treatment with DMSO, benzene, DCC, pyridine and trifluoro- 25 acetic acid utilizing an oxidation procedure analogous to that of Pfitzer, K.E. and Moffat, J.G. (1963) *J. Am. Chem. Soc.*, 85:3027. The 3-aldehydic intermediate can be blocked for use as an aldehyde or it can be further converted to a hydrazino compound. Thus, the 3-aldehydic 30 intermediate is either then treated with 1,2-dianilinoethylene to afford a 3-diphenylimidazolidino-protected 3-aldehyde compound or the 3-aldehydic intermediate is treated with hydrazine hydrate and sodium cyanoborohydrate in acetonitrile to give the corresponding 3-hydrazino 35 compound. These compounds are then used in further

synthesis as per the teachings of above-noted Patent Application Serial No. 703,619 to yield corresponding hydrazino and hydrazine-linked, heterocyclic-base-substituted cyclobutane dimers. Such dimers can be incorporated into the oligonucleotide surrogates or extended to form longer chain hydrazino or hydrazine-linked oligonucleotide surrogates. Thus, oligonucleotide surrogates of the invention having linking moieties of the structures $\text{CH}=\text{N}-\text{NH}-\text{CH}_2$ and $\text{CH}_2-\text{NH}-\text{NH}-\text{CH}_2$ are prepared in a facile manner.

Further protected 1-adenyl, guanyl or cytidyl or unprotected thymidyl and uridyl-3-monomethoxytrityl-3-hydroxymethyl-cyclobutane are converted to the corresponding 3-N-hydroxyphthalimide-3-monomethoxytrityl-3-hydroxymethyl-cyclobutanes by treatment of 3-monomethoxytrityl-3-hydroxymethyl-cyclobutane compounds with N-hydroxyphthalimide, triphenylphosphine, and diisopropylazodicarboxylate in dry DMF. The N-hydroxyphthalimido compound is then converted to a corresponding 3-amino intermediate compound by treatment with methylhydrazine in dry CH_2Cl_2 under anhydrous conditions, as per the teaching of above-referenced Patent Application Serial No. 703,619.

Reaction of 3-amino cyclobutane compounds with 3-aldehydic cyclobutane compounds yield oxime-linked compounds. Such oximes can be reduced with sodium cyanoborohydride to form hydroxylamine linkages, if desired. Thus, oligonucleotide surrogates of the invention having linking moieties of the structures $\text{CH}_2-\text{O}-\text{NH}-\text{CH}_2$ and $\text{CH}_2-\text{O}-\text{N}=\text{CH}$ are prepared in a facile manner.

Oligonucleotide surrogates of the invention having sulfonate linkages are prepared by reacting protected 1-adenyl, guanyl or cytidyl or unprotected thymidyl and uracyl-3-monomethoxytrityl-3-hydroxymethyl-cyclobutaneas per the procedures of Musicki, B and Widlanski, T.S.

- 27 -

(1990) *J. Organic Chem.*, 55:4231. Phosphoramidates linkages are formed as per the procedure of Gryaznov, S.M. and Sokolova, N.I. (1990) *Tetrahedron Letters*, 31:3205; formacetal linkages as per the procedure of Matteucci, M. 5 (1990) *Tetrahedron Letters*, 31:2385; phosphonate linkages as per the procedure of Mazur, A., Troop, B.E. and Engel, R. (1984) *Tetrahedron*, 40:3949; carbamate linkages as per the procedure of Stirchak, E.P. and Summerton, J.E. (1987) *J. Organic Chem.*, 52:4202; aminoacyl linkages as per the 10 procedure of Li, C and Zemlicka (1977) *J. Organic Chem.*, 42:706 and Nyilas, A., Glemare, C. and Chattopadhyaya, J. (1990) *Tetrahedron*, 46:2149; methylene linkages as per the procedure of Veeneman, G.H., van der Marcel, G.A., van den Elst, H. and van Boom, J.H. (1990) *Recl. Trav. Chim. Pays-* 15 *Bas*, 109:449; and silyl linkages as per the procedure of Ogilvie, K.K. and Cormier, J.F. (1985) *Tetrahedron Letters*, 26:4159.

The oligonucleotide surrogates of this invention can be used in diagnostics, therapeutics, and as research 20 reagents and kits. For therapeutic use the oligonucleotide surrogates are administered to an animal suffering from a disease modulated by a protein. It is preferred to administer to patients suspected of suffering from such a disease an amount of the oligonucleotide surrogate that 25 is effective to reduce the symptoms of that disease. One skilled in the art may determine optimum dosages and treatment schedules for such treatment regimens.

It is generally preferred to administer therapeutic oligonucleotide surrogates in accordance with this 30 invention internally such as orally, intravenously, or intramuscularly. Other forms of administration, such as transdermally, topically, or intra-lesionally may also be useful. Inclusion in suppositories may also be useful. Use of the oligonucleotide surrogates of this invention 35 in prophylaxis is also likely to be useful. Use of

GP 055957

- 28 -

pharmacologically acceptable carriers is also preferred for some embodiments.

Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples, which are not intended to be limiting.

Experimental

General - Flash chromatography: silica gel Merck 60, 230 - 400 mesh ASTM; Alumina B act I: ICN Biomedicals N° 02072; Hyflo: Fluka N° 56678; Molecular sieves: 0.4 and 0.3 nm, beads about 2 mm, Merck No 5704 and 5708; TLC plates: Merck silica gel 60 f₂₅₄ precoated, layer thickness: 0.25 mm; Solvents: Dichloromethane: stored over 0.4 nm molecular sieves; Dimethoxyethane (DME): passed over basic alumina before use; Dimethylsulfoxide (DMSO): distilled under vacuum and stored over 0.4 nm molecular sieves; Dioxane: passed over basic alumina before use; Ethanol: stored over 0.3 nm molecular sieves; Pyridine: distilled and stored over 0.4 nm molecular sieves; Tetrahydrofuran (THF): distilled over potassium - naphthalene and stored over 0.4 nm molecular sieves; Toluene: distilled and stored over 0.4 nm molecular sieves; Triethylamine: distilled and stored over 0.4 nm molecular sieves; Solvents for chromatography: ratios given in v/v, distilled before use; Melting point: Büchi apparatus; I.R.: Perkin - Elmer model 881, film: 1 drop substance between 2 sodium chloride plates; NMR: 200 MHz: Varian GEM 200; 300 MHz: Varian GEM 300; 400 MHz: Bruker WM 400, solvent internal reference: CDCl₃: ¹H: 7.265 PPM, ¹³C: 77.00 PPM; CD₃OD: ¹H: 3.34 PPM, ¹³C: 49.00 PPM; DMSO: ¹H: 2.50 PPM, ¹³C: 39.70 PPM; abbreviations: s, singlet; d, doublet; t, triplet; q, quadruplet; quint, quintuplet; Carbon NMR: completely decoupled and APT spectra were

GP 055958

SUBSTITUTE SHEET

- 29 -

usually recorded, off-resonance decoupled spectra were recorded only if necessary; U.V.: Perkin - Elmer Lambda 9 UV/VIS/NIR spectrometer; M.S.: 2 AB, HF apparatus, FAB technique, thioglycine as solvent: numbering on aromatic rings: r, reference; o, ortho; m, meta; p, para; on heterocyclics: adenine: ad + number; guanine: gu + number; thymine: thy + number; uracil: ur + number; cytosine: cy + number.

EXAMPLE 1

10 1-Benzoyloxy-3,3-bis-carbethoxy-cyclobutane 1.

Compound 1 was prepared according to the literature procedures of Avram, M., Nenitzescu, C.D. and Maxim, C.D. (1957) *Chem. Ber.*, 90:1424 and Safanda, J. and Scobotka, P. (1982) *Collect. Czech. Chem. Commun.* 47:2440 with minor improvements. Malonic acid diethyl ester (258.6 ml, 1.703 moles) was added neat over a two hours period to a suspension of sodium hydride (51.10g, 1.703 moles, Fluka N^o 71614: 80 % NaH in oil) in dioxane (1000 ml). This solution was stirred 90 min at room temperature. 1-Bromo-20 2-benzoyloxy-3-chloro-propane (500g, 1.789 moles) was added neat over a one hour period. The mixture was stirred for one hour at room temperature, followed by 24 hours at 125° C. After slow cooling to room temperature, a like quantity of sodium hydride was added neat in 5 g portions 25 over one hour. The suspension was slowly heated to 125° C and mechanically stirred for 120 hours at this temperature. The workup was as described in the literature references. Thus, compound 1 was first purified by distillation 172° C at 0.6 Torr, followed by flash chromatography (tertobutylmethylether/hexane = 1/99 to 2/8) 30 to afford 1: 382.5 g, 73.3 % as a colourless oil.

EXAMPLE 2

1-Benzyl-oxy-3,3-bis-hydroxymethyl-cyclobutane 2.

A solution of 1 (95.8 g, 313 mmoles) in dimethoxyethane (80 ml) was added dropwise at room temperature under argon to a suspension of lithium aluminum hydride (15 g, 395 mmoles) in dimethoxyethane (360 ml). The addition was done so as to maintain the reaction temperature under 50° C. (TLC control: ethyl acetate; Rf = 0.30). The reaction mixture was stirred under argon at room temperature for 48 hours. After completion of the reaction, water (10 ml) was slowly added with vigorous stirring. The reaction mixture was then transferred into a 2 l flask containing silica gel (800 ml) and the solvent was removed under vacuum until a fine powder was obtained. This powder was added to a 5 cm Hyflo pad on a fritteglass and washed with ethyl acetate (400 ml fractions with TLC control). The fractions containing product were evaporated to give 55 g of crystalline 2 (79 % crude). After recrystallization from ethyl-acetate/hexane 43.2 g, 62 % of colourless crystals were obtained. The mother liquors were purified by flash chromatography (eluent: ethyl acetate/hexane = 5/5 to 7/3) to give 5 g, 7.2 % of crystals; MW = 222. 285; MP = 67.5 - 68.5° C; I.R. (film): 3368, 3031, 2928, 2870, 1721, 1496, 1454; ¹H (CDCl₃ at 200 MHz): d in PPM: 7.30 (s: 5 H_{ar}); 4.40 (s: CH₂, Bzl); 4.06 (quint: H₁); 3.66 (s: CH₂O_a); 3.62 (s: CH₂O_b); 3.15 (2 OH); 2.16 (m: ABX, H_{2a} + H_{3a}); 1.78 (m: ABX, H_{2b} + H_{4b}); ¹³C (CDCl₃ at 50 MHz): d in PPM: 138.56: C_r; 128.95: C_o; 128.45: C_m; 128.25: C_p; 71.01: CH₂O_a; 70.48: CH₂O_b; 69.43: CH₂, Bzl; 69.00: C₁; 37.35: C₃; 34.55: C₂ + C₄.

Anal. calculated for C₁₃H₁₈O₃: C 70.25, H 8.16, O 21.60; found: C 70.09, H 8.22, O 21.64.

GP 055960

- 31 -

EXAMPLE 3

O⁵, O^{5'}-Isopropylidene-ether of 1 α -benzyloxy-3,3-bis-hydroxymethyl-cyclobutane 3.

2,2-dimethoxypropane (19.9 ml, 162 mmoles) was slowly
 5 added to a solution of 2 (12 g, 54 mmoles) and p-toluene-
 sulfonic acid (1 g) in dimethylformamide (240 ml) (TLC
 control: ethyl acetate; R_f = 0.15). The reaction was
 stirred under argon at room temperature for 20 hours.
 Ethyl acetate (500 ml) was then added to this reaction
 10 mixture and the resulting solution was washed 4 times with
 brine (4 x 150 ml). The organic phase was dried over
 magnesium sulfate and evaporated to dryness to give 3,
 13.7g, 96.5 % as a colourless oil which crystallized after
 a few days in the refrigerator. The crystals required no
 15 further purification; MW = 262.350; MP = 54 - 56° C; I.R.
 (film): 3419, 3030, 2997, 2955, 2922, 2866, 2350, 1728,
 1606, 1584, 1497; ¹H (CDCl₃ at 200 MHz): d in PPM (J: Hz):
 7.32 (s: 5 H_{ar}); 4.38 (s: CH₂, Bzl); 4.02 (quint: J = 6.5,
 H₁); 3.70 (s: CH₂O_a); 3.67 (s: CH₂O_b); 2.19 (m: ABX, J =
 20 13.5, 6.5, H_{2a} + H_{4a}); 1.80 (m: ABX, J = 13.5, 6.5, H_{2b} +
 H_{4b}); 1.37 (s: 2 CH₃); ¹³C (CDCl₃ at 50 MHz): d in PPM:
 138.56: C_r; 128.93: C_m; 128.40: C_o; 128.20: C_p; 98.17:
 C_{iPr}; 70.48: CH₂O_a; 70.42: CH₂O_b; 69.26: C₁; 68.94: CH₂,
 Bzl; 36.54: C₂ + C₄; 30.80: C₃; 24.04: 2 CH₃.
 25 Anal. calculated for C₁₆H₂₂O₃: C 73.25, H 8.45, O
 18.30; found: C 73.10, H 8.56, O 18.60.

EXAMPLE 4

O⁵, O^{5'}-Isopropylidene-ether of 1 α -hydroxy-3,3-bis-hydroxymethyl-cyclobutane 4.

30 Degussa palladium (2 g) in dimethoxyethane (350 ml)
 was first placed under a hydrogen atmosphere, 3 (44 g, 168
 mmoles) was then added neat. The reaction mixture was
 shaken vigorously at room temperature under a hydrogen

GP 055961

SUBSTITUTE SHEET

- 32 -

pressure of 1 atmosphere until 1 equivalent was absorbed (approximately 1 hour). After filtration of the catalyst over Hyflo, the solution was evaporated to dryness to afford 4 as a colourless syrup, 28.1 g, 97 %; $C_9H_{16}O_3$; MW = 172.225; I.R. (film): 3336, 2930, 2873, 1712, 1652, 1465; 1H ($CDCl_3$ at 200 MHz): d in PPM: 4.20 (quint: H_1); 3.68 (s: CH_2O_a); 3.64 (s: CH_2O_b); 2.25 (m: ABX, $H_{2a} + H_{4a}$); 1.65 (m: ABX, $H_{2b} + H_{4b}$); 1.35 (s: 2 CH_3); ^{13}C ($CDCl_3$ at 50 MHz): d in PPM: 98.22: C_{1Pr} ; 70.50: CH_2O_a ; 68.79: CH_2O_b ; 63.51: C_1 ; 39.05: $C_2 + C_4$; 30.00: C_3 ; 24.02: 2 CH_3 .

EXAMPLE 5

$O^5, O^{5'}$ -Isopropylidene-ether of 1 α -p-bromo-benzene-sulfonyl-3,3-bis-hydroxymethyl-cyclobutane 5.

A mixture of 4 (65 g, 37.8 mmoles) and triethylamine (15.8 ml, 113.2 mmoles) in dichloromethane (150 ml) was stirred under argon at 0° C. A solution of p-bromo-benzenesulfonylchloride (11.57 g, 45.3 mmoles) in dichloromethane (50 ml) was slowly added at 0° C. The reaction mixture was stirred for 60 hours at room temperature (TLC control: ethyl acetate/hexane = 5/5; Rf = 0.5). Ethyl acetate (400 ml) was added and the solution washed 4 times with brine (4 x 200 ml). The organic phase was dried over magnesium sulfate and the solvent evaporated. The obtained syrup was purified by flash chromatography (ethyl acetate/hexane/triethylamine = 7/3/0.1 to 1/1/0.1) to afford 5, 11.4 g, 77.2 % as colourless crystals; MW = 391.285; MP = 99 - 101° C; I.R. (KBr): 2970, 2920, 2840, 1570, 1365, 1185; 1H ($CDCl_3$ at 200 MHz): d in PPM (J in Hz): 7.72 (m: 4 H_{ar}); 4.84 (quint.: J = 6.9 H_1); 3.67 (s: CH_2O_a); 3.65 (s: CH_2O_b); 2.28 (m: ABX, $H_{2a} + H_{4a}$); 1.95 (m: ABX, $H_{2b} + H_{4b}$); 1.35 (s: 2 CH_3); ^{13}C ($CDCl_3$ at 50 MHz): d in PPM: 136.44: C_r ; 133.18: C_m ; 129.77: C_o ; 129.63: C_p ;

GP 055962

SUBSTITUTE SHEET

- 33 -

98.39: C_{iPr}; 72.11: CH₂O_a; 69.83: CH₂O_b; 67.98: C₁; 36.99: C₂ + C₄; 31.52: C₃; 23.90: 2 CH₃.

Anal. calculated for C₁₅H₁₉ErSO₅: C 46.05, H 4.90, O 20.45, S 8.19, Br 20.42; found: C 46.09, H 5.05, O 20.32, S 8.20, Br 20.42.

EXAMPLE 6

*O*⁵,*O*^{5'}-Isopropylidene-ether of 1 α -adenyl-3,3-bis-hydroxymethyl-cyclobutane 6.

A mixture of 5 (20 g, 51.1 mmoles), adenine (20.72 g, 153.3 mmoles) and diazabicycloundecene (23 ml, 23.34 mmoles) in dimethylsulfoxide (800 ml) were stirred under argon at 80° C for 48 hours (TLC control: ethyl acetate/methanol = 8/2, R_f = 0.29; detection: 1) chlorine 2) potassium iodide). Saturated sodium bicarbonate (200 ml) and water (800 ml) were added and the solution was extracted 7 times with ethyl acetate (7 x 200 ml). The collected organic fractions were washed with brine (200 ml), dried over sodium sulfate and purified by flash chromatography (ethyl acetate/methanol/triethyl-amine = 95/5/0.1) to afford 6, 11.1 g, 75 % as colourless crystals; MW = 289.339; MP = 251° C after crystallization from water/ethanol; I.R. (KBr): 3490, 3420, 3180, 2990, 2850, 2750, 1650, 1600, 1580, 1480; ¹H (CDCl₃ at 200 MHz): δ in PPM: 8.30 (s: H_{2ad}); 7.82 (s: H_{8ad}); 5.60 (s: NH₂); 4.95 (quint: H₁); 3.90 (s: CH₂O_a); 3.87 (s: CH₂O_b); 2.55 (m: ABX, H₂ + H₄); 1.40 (s: 2 CH₃); ¹³C (CDCl₃ at 50 MHz): δ in PPM: 155.8: C_{6ad}; 152.2: C_{2ad}; 149.4: C_{4ad}; 138.8: C_{8ad}; 120.0: C_{5ad}; 97.8: C_{iPr}; 68.9: CH₂O_a; 66.8: CH₂O_b; 44.3: C₁; 39.7: C₃; 35.2: C₂; 31.3: C₄; 23.1: 2 CH₃; U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max): 205 (19820), 259 (13940).

Anal. calculated for C₁₄H₁₉N₅O₂: C 58.12, H 6.62, N 24.21, O 11.06; found: C 58.18, H 6.88, N 24.19, O 11.30.

GP. 055963

SUBSTITUTE SHEET

- 34 -

EXAMPLE 7

*O*⁵,*O*^{5'}-Isopropylidene-ether of 1 α -thymidyl-3,3-bis-hydroxymethyl-cyclobutane 7 and 1,3-bis-(*O*⁵,*O*^{5'}-isopropylidene-ether of 3,3-bis-hydroxymethyl-cyclobutyl)thymine 8.

A mixture of 5 (20.26 g, 51.8 μ moles), thymine (26.12 g, 207.1 μ moles) and diazabicycloundecene (31 ml, 31.5 μ moles) in dimethylsulfoxide (800 ml) were stirred under argon at 80° C for 48 hours (TLC control: methanol/ethyl acetate = 1/9; R_f = 0.52 and 0.48; detection: 1) chlorine 2) potassium iodide). Saturated sodium bicarbonate (200 ml) and water (800 ml) were added and the solution was extracted 7 times with ethyl acetate (7 x 200 ml). The collected organic fractions were washed with brine (200 ml), dried over sodium sulfate and purified by flash chromatography (ethyl acetate/hexane/triethylamine = 5/5/0.01 to 7/3/0.01) to afford fraction 1: R_f = 0.47 (methanol/ethyl acetate = 1/9) compound 8, 3.85 g, 34.2 %; fraction 2: R_f = 0.52 (methanol/ethyl acetate = 1/9) compound 7, 7.92 g, 54.6 %.

*O*⁵,*O*^{5'}-Isopropylidene-ether of 1 α -thymidyl-3,3-bis-hydroxymethyl-cyclobutane 7:

Fraction 2; MW = 280.326; MP = 198 - 201° C; I.R. (KBr): 3190, 3000, 2950, 2860, 1680; ¹H (CDCl₃ at 200 MHz): δ in PPM: 9.94 (s: NH); 7.07 (s: H_{thy}); 4.74 (quint: H₁); 3.78 (s: CH₂O_a); 3.69 (s: CH₂O_b); 2.36 (m: ABX, H_{2a} + H_{4a}); 1.99 (m: ABX, H_{2b} + H_{4b}); 1.78 (s: CH₃ thy); 1.35 (s: 2 CH₃); ¹³C (CDCl₃ at 50 MHz): δ in PPM: 164.71: CO; 151.60: CO; 137.15: C_{6thy}; 111.12: C_{5thy}; 98.54: C_{iPr}; 69.80: CH₂O_a; 67.60: CH₂O_b; 47.21: C₁; 35.06: C₂ + C₄; 31.66: C₃; 23.94: 2 CH₃; 12.73: CH₃ thy; U.V. (methanol, 0.5 x 10⁻⁴ mole/l): 1 max in nm: (e max): 209 (15200); 270 (18000).

GP 055964

SUBSTITUTE SHEET

- 35 -

Anal. calculated for $C_{14}H_{20}N_2O_4$: C 59.99, H 7.19, N 10.00, O 22.83; found: C 59.64, H 7.22, N 9.71, O 22.55.

1,3-Bis-($O^5, O^{5'}$ -isopropylidene-ether of 3,3-bis-hydroxymethyl-cyclobutyl)-thymine 8.

5 Fraction 1; MW = 434.536; MP = 154 - 155° C; I.R. (KBr): 3000, 2940, 1610, 1570; 1H ($CDCl_3$ at 200 MHz): d in PPM: 7.90 (s: H_{thy}); 5.25 (quint: H_1); 5.07 (quint: H_1); 3.70 (s: 4 CH_2O); 2.42 (m: ABX, 4 H, $H_{2a} + H_{4a}$); 1.98 (m: ABX, 4 H, $H_{2b} + H_{4b}$); 1.78 (s: CH_3_{thy}); 1.35 (s: 4 CH_3);
 10 ^{13}C ($CDCl_3$ at 50 MHz): d in PPM: 168.69: CO; 163.26: CO; 157.93: C_{6thy} ; 111.58: C_{5thy} ; 98.16: C_{iPr} ; 98.11: C_{iPr} ; 68.78: CH_{2O_a} ; 68.72: CH_{2O_a} ; 67.70: CH_{2O_b} ; 67.64: CH_{2O_b} ; 53.60: C_1 ; 36.77: C_2 ; 36.72: C_4 ; 31.87: C_3 ; 31.39: C_3 ; 23.98: 2 CH_3 ; 12.06: CH_3_{thy} ; U.V. (methanol, 0.5×10^{-4}
 15 mole/l): 1 max in nm: (e max) : 215 (5520); 265 (3940).

Anal. calculated for $C_{23}H_{34}N_2O_6$: C 63.57, H 7.89, N 6.45, O 22.09; found: C 63.76, H 7.77, N 6.46, O 22.12.

EXAMPLE 8

1 α -Adenyl-3,3-bis-hydroxymethyl-cyclobutane 9.

20 10 Drops of aqueous 2M hydrochloric acid were added at room temperature to a solution of 6 (1.09 g, 2.77 mmoles) in dioxane (5 ml). The solution was stirred for 1 hour, evaporated to dryness and crystallized from water. The crystals obtained were not pure as shown by TLC
 25 (chloroform/methanol/water = 70/30/5), therefore the mixture of 9 and sodium chloride was purified by flash chromatography (eluent: chloroform/methanol/water = 93/6/1 to 70/30/5). 9, 650 mg, 70 % was obtained as colourless crystals; MW = 249.275; MP = 217 - 218° C; I.R. (film):
 30 3304, 3145, 2993, 2856, 1673, 1603, 1569; 1H (CD_3OD at 200 MHz): d in PPM: 8.05 (s: H_{2ad}); 7.95 (s: H_{8ad}); 4.80 (quint: H_1); 3.48 (s: CH_2O_a); 3.42 (s: CH_2O_b); 2.35 (m: H_2

GP 055965

SUBSTITUTE SHEET

- 36 -

+ H₄); ¹³C (CD₃OD at 50 MHz): d in PPM: 156.67: C_{2ad}; 143.97: C_{8ad}; 70.40: CH₂O_a; 69.59: CH₂O_b; 48.27: C₁; 43.64: C₃; 37.12: C₂ + C₄; U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max) : 194 (21200); 206 (21000); 262 (13780).

5 Anal. calculated for C₁₁H₁₅N₅O₂: C 53.00, H 6.07, N 28.10, O 12.84; found: C 53.05, H 6.29, N 27.87, O 12.71.

EXAMPLE 9

1,3-Bis-(3,3-bis-hydroxymethyl-cyclobutyl)-thymine
10.

10 Drops of aqueous 2M hydrochloric acid were added at room temperature to a solution of 8 (1.48 g, 3.41 nmoles) in dioxane (5 ml). Analogous to the procedure for compound 9, 10 (846 mg, 70 %) was obtained as colourless crystals; MW = 240.261; MP = 128 - 130° C; IR (film):
15 3346, 2934, 2870, 1604, 1575, 1435, 1329, 1293; ¹H (CD₃OD at 200 MHz): d in PPM: 7.70 (s: H_{thy}); 5.05 (quint: H₁); 4.87 (quint: H₁); 3.44 (s: CH₂O_a); 3.42 (s: CH₂O_a); 3.38 (s: CH₂O_b); 3.36 (s: CH₂O_b); 2.15 (m: H_{2a} + H_{4a}); 1.78 (m: H_{2b} + H_{4b}); 1.76 (s: CH₃_{thy}); ¹³C (CD₃OD at 50 MHz): d in
20 PPM: 173.87: CO; 167.06: CO; 161.08: C_{6thy}; 115.45: C_{5thy}; 72.27: CH₂O_a; 71.59: CH₂O_b; 70.05: C₁; 69.97: C₁; 42.67: C₃; 42.66: C₃; 38.34: C₂ + C₄; 38.19: C₂ + C₄; 15.62: CH₃_{thy}; U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max): 268 (9640).

25 Anal. calculated for C₁₇H₂₆N₂O₆: C 57.61, H 7.39, N 7.90, O 27.09; found: C 57.24, H 7.38, N 7.89, O 27.12.

EXAMPLE 10

1α-Thymidyl-3,3-bis-hydroxymethyl-cyclobutane 11.

10 Drops of aqueous 2M hydrochloric acid were added
30 at room temperature to a solution of 7 (1.05 g, 3.73 nmoles) in dioxane (5 ml). Analogous to the procedure for compound 10, 11 (700 mg, 78 %) was obtained as colourless

GP 055966

- 37 -

crystals; MW = 354.406; MP = 207 - 206° C; Rf = 0.23, methanol/ethyl acetate = 1/9; I.R. (KBr): 3170, 3040, 2990, 2950, 2870, 1690, 1660; ¹H (CD₃OD at 400 MHz): δ in PPM (J: Hz): 7.33 (q: H_{thy}); 4.72 (quint: J: 8.5, H₁);
5 3.47 (s: CH₂O_a); 3.37 (s: CH₂O_b); 2.07 (d: J: 8.5, H₂ - H₄); 1.78 (s: CH₃_{thy}); ¹³C (CD₃OD at 50 MHz): δ in PPM: 176: CO; 167: CO; 142.29: CH_{thy}; 70.45: CH₂O_a; 69.84: CH₂O_b; 49.68: C₁; 43.2: C₃; 35.77: C₂ + C₄; 16.27: CH₃_{thy}; U.V. (water, 0.5 x 10⁻⁴ mole/l): λ max in nm (ε max): 211
10 (8840); 274 (10520).

Anal. calculated for C₁₁H₁₆N₂O₄: C 54.99, H 6.71, N 11.66, O 26.64; found: C 54.86, H 6.74, N 11.65, O 26.56.

EXAMPLE 11

1α-Thymidyl-3β-hydroxymethyl-3α-methoxytrityloxy-
15 methyl-cyclo-butane 12 and 1α-thymidyl-3α-hydroxymethyl-3β-methoxytrityloxymethyl-cyclobutane 13.

11 (314 mg, 1.307 mmoles) was evaporated 3 times with pyridine (3 x 10 ml). Methoxytritylchloride (316.5 mg, 1.03 mmoles) was added under argon to a solution of 11 in
20 pyridine (10 ml). The reaction was stirred at room temperature for 8 hours (TLC control: ethyl acetate/hexane = 8/2). More methoxytritylchloride (100 mg, 0.32 mmoles) was added in two portions after 5 hours. The reaction mixture was stirred 15 hours at room temperature. Five
25 spots were visible on TLC (chloroform/methanol/triethylamine = 95/5/1; spot 1: Rf = 0.99, degradation product of methoxytritylchloride; spot 2: Rf = 0.95, bis-methoxytrityl-derivative; spot 3: Rf = 0.40, compound 12; spot 4: Rf = 0.35, compound 13; spot 5: Rf = 0.05, unreacted
30 diol 11. Other experiments have shown that adding more methoxytritylchloride did not diminish the amount of unreacted diol 11 but increased the amount of bis-methoxytrityl-derivative. Sodium bicarbonate (10 ml, 1M) was

added, the solution extracted 4 times with ethyl acetate (4 x 20 ml) and the organic phase dried over sodium sulfate. These products were separated by flash chromatography (eluent: chloro-form/acetone/triethylamine = 5 99/1/1 slowly to 80/20/1) to give fraction 1: 70 mg (8.9 %); fraction 2, 12: 234 mg (34.9 %); fraction 3, 13: 231 mg (41.9 %); fraction 4, 11: 20 mg (6.4 %).

1 α -Thymidyl-3,3-bis-methoxytrityloxymethyl-cyclo-butane: C₅₁H₄₈N₂O₆: MW = 784.954; fraction 1; Rf = 0.95, 10 chloroform/methanol/triethylamine = 95/5/1 ; 70 mg (8.9 %).

1 α -Thymidyl-3 β -hydroxymethyl-3 α -methoxytrityloxy-methyl-cyclobutane 12:

Fraction 2; Rf = 0.40, chloroform/methanol/triethyl-
15 amine = 95/5/1; 234 mg (34.9 %); MW = 512.608; MP = 126°
C; ¹H (CDCl₃ at 400 MHz): d in PPM (J: Hz): 8.25 (s: NH);
7.43 (m: 4 H_{ar}); 7.31 (dd: 6 H_{ar}); 7.25 (m: 2 H_{ar}); 7.13
(q: J = 1.5; H_{thy}); 6.85 (d: 2 H_{ar}); 4.94 (quint: J: 9.0;
H₁); 3.78 (s: CH₂O); 3.72 (d: J: 4.5; CH₂OH); 3.24 (s:
20 CH₂OTrOMe); 2.31 (ddd: ABX J: 3.0, 9.0, 11.0; H_{2a} + H_{4a});
2.10 (ddd: ABX J: 3.0, 9.0, 10.2; H_{2b} + H_{4b}); 2.01 (t: J:
4.5; OH); 1.72 (d: J: 1.5; CH₃ thy); ¹H (CDCl₃ at 400 MHz)
NOE experiments: Irradiation on H₁: positive NOE on CH₂OH,
H_{2b} + H_{4b} and no effect on H_{2a} + H_{4a}; irradiation on CH₂OH:
25 positive NOE on H₁ and H_{2b} + H_{4b}; irradiation on CH₂OTrOMe:
positive NOE on CH₂OH, H_{2a} + H_{4a} and no effect on H₁;
irradiation on H_{2a} + H_{4a}: positive NOE on H_{2b} + H_{4b},
CH₂OTrOMe and no effect on H₁; irradiation on H_{2b} + H_{4b}:
positive NOE on H_{2a} + H_{4a}, H₁, CH₂OH and no effect on
30 CH₂OTrOMe; U.V. (methanol, 0.5 x 10⁻⁴ mole/l): λ max in nm
(ϵ max): 274 (10720) FAB-MS: 513 = MH⁺; 535 = M + Na; 435
= M - Ph; 273 = MeOTr⁺; 241 = M - TrOMe⁺; 195 = MeOTr -
Ph⁺; 165 = MeOTr - PhOMe⁺; 127 = Thy + H⁺

- 39 -

Anal. calculated for $C_{31}H_{32}N_2O_5 + 0.42 H_2O$: C 71.58, H 6.36, N 5.39, O 16.67; found: C 71.58, H 6.37, N 5.46, O 16.72.

1 α -Thymidyl-3 α -hydroxymethyl-3 β -methoxytrityloxy-
5 methyl-cyclobutane 13:

Fraction 3: Rf = 0.35, chloroform/methanol/triethyl-
amine = 95/5/1; 281 mg (41.9 %); MW = 512.608; MP = 120°
C; 1H (CDCl₃ at 400 MHz): d in PPM (J: Hz): 8.25 (s: NH);
7.43 (m: 4 H_{ar}); 7.36 (q: J = 1.5; H_{thy}); 7.31 (m: 6 H_{ar});
10 7.23 (m: 2 H_{ar}); 6.86 (m: 2 H_{ar}); 4.81 (quint: J = 8.5;
H₁); 3.82 (s: CH₃O); 3.64 (d: J = 3.5; CH₂OH); 3.26 (s:
CH₂OTROME); 2.28 (m: A₂X; H₂ + H₄); 2.06 (t: J = 3.7; OH);
1.94 (d: J = 1.5; CH₃ thy); 1H (CDCl₃ at 400 MHz) NOE
experiments: irradiation on H₁: positive NOE on CH₂OTROME
15 and H₂ + H₄; irradiation on CH₂OH: positive NOE on CH₂O-
TROME, H₂ + H₄ and no effect on H₁; irradiation on CH₂O-
TROME: positive NOE on H₁, H₂ + H₄ and CH₂OH; U.V. (methan-
ol, 0.5 x 10⁻⁴ mole/l): λ max in nm (e max): 274 (10740);
FAB-MS: 513 = M + H⁺; 535 = M + Na; 435 = M - Ph; 241 = M
20 - TROME; 273 = MeOTr⁺; 241 = M - TROME⁺; 195 = MeOTr -
Ph⁺; 165 = MeOTr - PhOMe⁺; 127 = Thy + H⁺.

Anal. calculated for $C_{31}H_{32}N_2O_5 + 0.50 H_2O$: C 71.38,
H 6.38, N 5.37, O 16.87; found: C 71.26, H 6.48 N 5.44,
O 16.65.

25 EXAMPLE 12

O⁵,O^{5'}-Isopropylidene-ether of 1 α -(N,N-dibenzoyl-
adenyl)-3,3-bis-hydroxymethyl-cyclobutane 16:

A pyridine solution of 6 (707 mg, 2.44 mmoles) was
evaporated 3 times to dryness (3 x 15 ml). Benzoyl
30 chloride (700 ml, 6.02 mmoles) was added neat dropwise to
a solution of 6 in pyridine (5 ml). The reaction mixture
was stirred 15 hours at room temperature (TLC control:

GP 055969

SUBSTITUTE SHEET

- 40 -

methanol/ethyl acetate = 2/8, $R_f = 0.55$). Water (20 ml) was added and the solution extracted twice with ethyl acetate (2 x 40 ml). The organic phase was dried over sodium sulfate and evaporated to dryness. The compound

5 was crystallized from chloroform/methanol to afford 16 (1.205 g, 99 %) as colourless crystals; MW = 494.533; MP = 221 - 222° C after crystallization from chloroform/methanol; I.R. (KBr): 3060, 2990, 2930, 2850, 1700, 1600; ^1H (CDCl_3 at 200 MHz): δ in PPM: 8.64 (s: $\text{H}_{2\text{ad}}$); 8.08

10 (s: $\text{H}_{8\text{ad}}$); 7.85 (d: $\text{H}_o \text{PhCO}$); 7.48 (t: $\text{H}_p \text{PhCO}$); 7.33 (m: $\text{H}_m \text{PhCO}$); 5.03 (quint: H_1); 3.92 (s: 2 CH_2O); 2.63 (d: $\text{H}_2 + \text{H}_4$); 1.42 (s: 2 CH_3); ^{13}C (CDCl_3 at 50 MHz): δ in PPM: 172.94: CO ; 164.00: $\text{C}_{6\text{ad}}$; 152.43: $\text{C}_{2\text{ad}}$; 144.14: $\text{C}_{8\text{ad}}$; 141.80: $\text{C}_{4\text{ad}}$; 134.64: $\text{C}_r \text{PhCO}$; 134.09: $\text{C}_p \text{PhCO}$; 133.52: $\text{C}_p \text{PhCO}$;

15 PhCO ; 130.66: $\text{C}_o \text{PhCO}$; 130.02: $\text{C}_o \text{PhCO}$; 129.24: $\text{C}_m \text{PhCO}$; 128.95: $\text{C}_m \text{PhCO}$; 112.80: $\text{C}_{5\text{ad}}$; 98.56: $\text{C}_{i\text{Pr}}$; 69.90: CH_2O_a ; 67.79: CH_2O_b ; 55.02: C_1 ; 45.83: C_3 ; 35.80: C_2 ; 32.24: C_4 ; 24.01: CH_3 ; U.V. (methanol, 0.5×10^{-4} mole/l): λ max in nm (ϵ max): 249 (21700).

20 Anal. calculated for $\text{C}_{28}\text{H}_{24}\text{N}_5\text{O}_4$: C 67.59, H 5.47, N 14.08, O 12.86, found: C 67.60, H 5.50, N 14.10, O 12.90.

EXAMPLE 13

$\text{O}^5, \text{O}^{5'}$ -Isopropylidene-ether of 1 α -(*N*-benzoyl-adenyl)-3,3-bis-hydroxymethyl-cyclobutane 17:

25 Concentrated ammonia (3 ml, 29 %) was added dropwise to a solution of 16 (718 mg, 1.47 mmoles) in THF (7.3 ml) and water (1.5 ml). The reaction mixture was stirred 4 hours at room temperature (TLC control): 4 spots were visible: spot 1: $R_f = 0.46$, ethyl acetate; $R_f = 0.54$,

30 ethyl acetate/methanol = 9/1, PhCONH_2 ; spot 2: $R_f = 0.36$, ethyl acetate; $R_f = 0.45$, ethyl acetate/methanol = 9/1, compound 16; spot 3: $R_f = 0.10$, ethyl acetate; $R_f = 0.42$, ethyl acetate/methanol = 9/1, compound 17; spot 4: $R_f =$

GP 055970

- 41 -

0.02, ethyl acetate; Rf = 0.26, ethyl acetate/methanol = 9/1, PhCOO⁻NH₄⁺. Water (20 ml) was added and the solution extracted 4 times with ethyl acetate (2 x 40 ml). The organic phase was dried over sodium sulfate and evaporated to dryness. These compounds were separated by flash chromatography (eluent: ethyl acetate/hexane = 5/5 to ethyl acetate/methanol = 8/2); MW = 393.448; MP = 180 - 182° C after crystallization from ethyl acetate/hexane; I.R. (film): 3500 - 3100, 2991, 2941, 2856, 1695, 1613; ¹H (CDCl₃ at 200 MHz): δ in PPM: 9.75 (s: NH); 8.23 (s: H_{2ad}); 8.08 (s: H_{8ad}); 8.02 (d: H_{o PhCO}); 7.48 (m: H_{p PhCO} + H_{m PhCO}); 5.02 (quint: H₁); 3.43 (s: 2 CH₂O); 2.57 (d: H₂ + H₄); 1.47 (s: 2 CH₃); ¹³C (CDCl₃ at 50 MHz): δ in PPM: 165.84: C=O; 152.54: C_{2ad}; 152.37: C_{6ad}; 150.26: C_{4ad}; 142.17: C_{8ad}; 134.15: C_{r PhCO}; 132.94: C_{p PhCO}; 128.95: C_{m PhCO}; 128.55: C_{o PhCO}; 123.91: C_{5ad}; 98.45: C_{iPr}; 69.71: CH_{2O_a}; 67.76: CH_{2O_b}; 62.64: C₁; 45.71: C₃; 35.88: C₂; 32.26: C₄; 24.01: CH₃; U.V. (methanol, 0.5 x 10⁻⁴ mole/l): λ max in nm: (ε max): 281 (20180).

Anal. calculated for C₂₁H₂₃N₅O₃: C 64.11, H 5.89, N 17.80, O 12.20; found: C 64.07, H 6.04, N 17.33, O 12.47

EXAMPLE 14

1α-(N,N-Dibenzoyl-adenyl)-3α-hydroxymethyl-3β-methoxytrityloxymethyl-cyclobutane 19 and 1α-(N,N-dibenzoyl-adenyl)-3β-hydroxymethyl-3α-methoxytrityloxymethyl-cyclobutane 20:

Aqueous 4M hydrochloric acid (10 drops) was added to a solution of 16 (209.5 mg, 0.421 μmoles) in dioxane (5 ml). The reaction mixture was stirred at room temperature for 5 hours (TLC control: dichloromethane/methanol = 9/1) and neutralized with pyridine. This compound 18, 1α-(N,N-dibenzoyl-adenyl)-3,3-bis-hydroxymethyl-cyclobutane, was not stable and could not be stored in the refrigerator.

GP 055971

SUBSTITUTE SHEET

First a pyridine solution of 18 was evaporated 3 times to dryness (3 x 10 ml), then methoxytritylchloride (130 mg, 0.421 mmole) was added in one portion to the pyridine solution (5 ml) of 18 in the presence of dimethylamino-
 5 pyridine (20 mg). The reaction mixture was stirred 15 hours at room temperature (TLC control: 2 runs with 2 different solvents 1: tertibutyl-methylether/hexane = 20/80; 2.: tertibutylmethylether/ethanol = 80/20) Five spots were visible on TLC: spot 1, Rf = 0.61, degradation
 10 product of methoxytritylchloride; spot 2, Rf = 0.48, bis-methoxytrityl-derivative; spot 3, Rf = 0.44, methoxytrityl-derivative; spot 4, Rf = 0.39, methoxytrityl-derivative; spot 5, Rf = 0.21, unreacted diol. Water (20 ml), sodium bicarbonate (1M, 20 ml) and ethyl acetate (50
 15 ml) were added. The aqueous phase was extracted 3 more times with ethyl acetate (3 x 50 ml), dried over sodium sulfate and evaporated to dryness. These compounds were separated by flash chromatography (eluent: tertibutyl-methylether/hexane = 2/8 to tertibutylmethylether/meth-
 20 anol: = 2/8) to give fraction 1: Rf = 0.48, 40 mg, 9.5 %; fraction 2: Rf = 0.44, compound 19, 46 mg, 15.0 %; fraction 3: Rf = 0.39, compound 20, 46 mg, 15.0 %; fraction 4: Rf = 0.21, compound 18, 30 mg, 14.3 %.

1 α -(N,N-Dibenzoyl-adenyl)-3,3-bis-methoxytrityloxy-
 25 methyl-cyclobutane:

Fraction 1, C₆₅H₅₅N₅O₆ MW = 1002.185; ¹H (CDCl₃ at 200 MHz): δ in PPM: 8.62 (s: H_{2ad}); 8.22 (s: H_{8ad}); 7.85 (m: H_{o Phco}); 7.50 ->7.20 (m: 10 H_{ar}); 6.82 (m: 4 H_{ar}); 4.96 (quint: H₁); 3.78 (s: CH₃O); 3.72 (s: CH₃O); 3.35 (s: CH₂O_a); 3.30 (s: CH₂O_b); 2.50 (m A₂X: H₂ + H₄).

1 α -(N,N-Dibenzoyl-adenyl)-3 α -hydroxymethyl-3 β -methoxytrityloxymethyl-cyclobutane 19:

Fraction 2, C₄₅H₃₉N₅O₅ ; MW = 729.838; ¹H (CDCl₃ at 200 MHz): δ in PPM: 8.63 (s: H_{2ad}); 8.24 (s: H_{8ad}); 7.85

(m: 4 H_{ar}); 7.50 ->7.20 (m: 18 H_{ar}); 6.82 (m: 2 H_{ar}); 4.98 (quint: H₁); 3.80 (s: CH₃O); 3.70 (s: CH₂OH); 3.30 (s: CH₂OTrOMe); 2.80 (m ABX: H_{2a} + H_{4a}); 2.50 (m ABX: H_{2b} + H_{4b}); ¹³C (CDCl₃ at 50 MHz): d in PPM: 172.97: 2 CO; 5 159.30: C_{6ad}; 153.79: C_p PhOMe; 152.34: C_{2ad}; 152.27: C_{4ad}; 144.66: C_{8ad}; 144.31: C_r Ph; 135.78: C_r PhOMe; 134.69: C_r PhCO; 133.49: C_p PhCO; 130.84: C_o PhOMe; 130.00: C_o PhCO; 129.23: C_m PhCO; 128.87: C_m Ph; 128.51: C_o Ph; 127.65: C_p Ph; 113.82: C_{5ad}; 113.75: C_m PhOMe; 69.55: CH₂O_a; 67.62: CH₂O_b; 10 55.58: C₁; 45.94: C₃; 38.44: C₂; 34.39: C₄.

1 α -(N,N-Dibenzoyl-adenyl)-3 β -hydroxymethyl-3 α -methoxytrityloxymethyl-cyclobutane 20:

Fraction 3, C₄₅H₃₉N₅O₅, MW = 729.838; ¹H (CDCl₃ at 200 MHz): d in PPM: 8.55 (s: H_{2ad}); 8.04 (s: H_{8ad}); 7.87 (m: 15 4 H_{ar}); 7.50 ->7.20 (m: 18 H_{ar}); 6.80 (m: 2 H_{ar}); 5.06 (quint: H₁); 3.80 (s: CH₂OH); 3.76 (s: CH₃O); 3.46 (s: CH₂OTrOMe); 2.55 (m A₂X: H₂ + H₄).

EXAMPLE 15

1 α -(N-Benzoyl-adenyl)-3,3-bis-hydroxymethyl-cyclobutane 21.

Aqueous 4M hydrochloric acid (200 ml) was added to a solution of 17 (1.00 g, 2.54 mmoles) in dioxane (10 ml) and water (1 ml). This mixture was stirred at room temperature for 5 hours (TLC control: ethyl acetate/methanol = 7/3), after the reaction was complete the solution was neutralized with solid sodium bicarbonate and evaporated to dryness. The obtained oil was purified by flash chromatography (eluent: ethyl acetate to ethyl acetate/methanol = 8/2) to afford 21 (700 mg, 78 %) as 30 colourless crystals. This compound was not very stable and could not be stored in the freezer for a longer time; C₁₈H₁₉N₅O₃; MW = 353.383; ¹H (CD₃OD at 200 MHz): d in PPM:

9.00 (s: H_{2ad}); 8.70 (s: H_{2ad}); 7.80 (d: H_{c PhCO}); 7.55 (dd: H_{p PhCO}); 7.35 (t: H_{m PhCO}); 5.06 (quint: H₁); 3.70 (s: CH_{2O_a}); 3.58 (s: CH_{2O_b}); 2.50 (d: H₂ + H₃); ¹³C (CD₃OD at 50 MHz): d in PPM: 171.80: CO; 154.22: C_{6ad}; 152.52: C_{2ad};
 5 149.14: C_{4ad}; 146.58: C_{8ad}; 136.87: C_{r PhCO}; 133.81: C_{p PhCO};
 131.62: C_{m PhCO}; 131.03: C_{o PhCO}; 120.81: C_{5ad}; 67.88: CH_{2O_a};
 66.55: CH_{2O_b}; 48.54: C₁; 41.85: C₃; 34.88: C₂ + C₄.

EXAMPLE 16

10 *1α-(N-Benzoyl-adenyl)-3α-hydroxymethyl-3β-methoxy-trityloxymethyl-cyclobutane 22 and 1α-(N-benzoyl-adenyl)-3β-hydroxymethyl-3α-methoxytrityloxymethyl-cyclobutane 23:*

Methoxytritylchloride (481 mg, 1.56 mmoles) was added under argon in 100 mg portions every 2 hours to a solution of 17 (500 mg, 1.41 mmoles) in pyridine (5 ml) in the
 15 presence of dimethylaminopyridine (100 mg). The reaction mixture was stirred at room temperature for 15 hours (TLC control: ethyl acetate/methanol = 8/2) Five spots were visible on TLC: spot 1: R_f = 0.95, degradation product of methoxytrityl-chloride; spot 2: R_f = 0.80, bis-methoxy-
 20 trityl-derivative; spot 3: R_f = 0.40, methoxytrityl-derivative; spot 4: R_f = 0.35, methoxytrityl-derivative; spot 5: R_f = 0.10, unreacted diol. Two more additions of methoxytritylchloride (2 x 100 mg) did not show further reaction. Water (1 ml) was added, the solution extracted
 25 6 times with ethyl acetate (6 x 15 ml), dried over sodium sulfate and evaporated to dryness. The mixture was separated by flash chromatography (eluent: ethyl acetate/hexane = 1/1 to ethyl acetate/methanol = 7/3) to afford: fraction 1: 100 mg, 8 % bis-methoxytrityl-deriv-
 30 ative; fraction 2: 240 mg, 27 % methoxytrityl-β-derivative 22; fraction 3: 80 mg, 9 % methoxytrityl-α-derivative 23; fraction 4: 50 mg, 10 % unreacted diol 17.

1 α -(N-Benzoyl-adenyl)- β , β -bis-methoxytrityloxymethyl-cyclobutane:

Fraction 1, C₅₆H₅₁N₅O₅, MW = 874.054; ¹H (CDCl₃ at 200 MHz): d in PPM: 9.55 (s: NH); 8.70 (s: H_{2ad}); 8.05 (d: 2 H_{ar}); 7.95 (s: H_{8ad}); 7.45 (m: 10 H_{ar}); 7.25 (m: 17 H_{ar}); 6.85 (m: 4 H_{ar}); 4.95 (quint: H₁); 3.75 (s: 2 CH₂O); 3.47 (s: CH₂O_a); 3.42 (s: CH₂O_b); 2.55 (m: H₂ + H₄).

1 α -(N-Benzoyl-adenyl)- β -hydroxymethyl- β -methoxytrityloxymethyl-cyclobutane 22:

10 Fraction 2, MP = 194° C; I.R. (film): 3396, 2935, 1700, 1611, 1581, 1508, 1453; ¹H (CDCl₃ at 360 MHz): d in PPM: 9.10 (s: NH); 8.79 (s: H_{2ad}); 8.12 (s: H_{8ad}); 8.05 (d: H_{o PhCO}); 7.61 (t: H_{p PhCO}); 7.53 (t: 2 H_{ar}); 7.49 (d: 4 H_{ar}); 7.39 -> 7.25 (m: 8 H_{ar}); 6.90 (d: H_{m PhOMe}); 4.98 (quint: H₁); 3.83 (s: CH₃O); 3.76 (s: CH₂OH); 3.32 (s: CH₂OTrOMe); 2.90 (m: ABX, H_{2a} + H_{4a}); 2.52 (m: ABX, H_{2b} + H_{4b}); ¹³C (CDCl₃ at 50 MHz): d in PPM: 165.29: CO; 159.16: C_{6ad}; 152.61: C_{2ad}; 152.55: C_{p PhOMe}; 150.80: C_{4ad}; 144.71: C_{8ad}; 142.65: C_{r Ph}; 135.70: C_{r PhOMe}; 134.16: C_{r PhCO}; 133.20: C_{p PhCO}; 130.95: C_{m PhCO}; 129.28: C_{o PhCO}; 128.88: C_{m Ph}; 128.44: C_{o Ph} + C_{o PhOMe}; 127.58: C_{p Ph}; 123.50: C_{5ad}; 113.71: C_{m PhOMe}; 67.77: CH₂O_a; 67.29: CH₂O_b; 55.77: C₁; 45.36: C₃; 39.32: C₂; 33.68: C₄; ¹H (CDCl₃ at 360 MHz) NOE experiments: irradiation on H₁: positive NOE on CH₂OTrOMe, H_{2b} + H_{4b}, H_{8ad} and no effect on CH₂OH, irradiation on CH₂OTrOMe: positive NOE on CH₂OH and on H₁; U.V. (ethanol, 0.5 x 10⁻⁶ mole/l): λ max in nm (e max): 231 (22740); 281 (17060); C₃₇H₃₅N₅O₄: MW: 625.730. FAB-MS: 626 = MH⁺; 522 = M - PhCO; 352 = M - TrOMe; 273 = MeOTr⁺; 240 = PhCONH-AdH-
30 +.

1 α -(N-Benzoyl-adenyl)-3 β -hydroxymethyl-3 α -methoxy-trityloxymethyl-cyclobutane 23:

Fraction 3, MP = 112° C; ¹H (CDCl₃ at 360 MHz): d in PPM: 9.16 (s: NH); 8.73 (s: H_{2ad}); 8.05 (d: H_{o PhCO}); 7.96 (s: H_{8ad}); 7.47 -> 7.15 (m: 13 H_{ar}); 6.67 (d: H_{m PhOMe}); 5.10 (quint: H₁); 3.85 (s: CH₂OH); 3.72 (s: CH₂O); 3.33 (s: CH₂OTrOMe); 2.53 (d: H₂ + H₄); ¹³C (CDCl₃ at 50 MHz): d in PPM: 165.30: CO; 159.12: C_{6ad}; 150.80: C_{2ad}; 150.40: C_{p PhOMe}; 148.00: C_{4ad}; 142.05: C_{8ad}; 135.83: C_{r PhOMe}; 134.29: C_{r PhCO}; 133.13: C_{p PhCO}; 130.81: C_{m PhCO}; 129.19: C_{o PhCO}; 128.89: C_{m Ph}; 128.54: C_{o Ph}; 128.43: C_{o PhOMe}; 127.58: C_{p Ph}; 123.52: C_{5ad}; 113.70: C_{m PhOMe}; 68.82: CH₂O_a; 67.19: CH₂O_b; 55.72: C₁; 45.77: C₃; 38.95: C₂; 34.53: C₄; ¹H (CDCl₃ at 360 MHz) NOE experiments: irradiation on H₁: positive NOE on CH₂OH, H₂ + H₄, H_{8ad} and no effect on CH₂OTrOMe; irradiation on CH₂OTrOMe: positive NOE on CH₂OH, H₂ + H₄ and no effect on H₁, irradiation on CH₂OH: positive NOE on CH₂OTrOMe, H₂ + H₄, OH and H₁, U.V. (ethanol, 0.5 x 10⁻⁴ mole/l): λ max in nm (e max): 230 (24880); 281 (18040); C₃₇H₃₅N₅O₄, MW = 625.730, FAB-MS: 626 = MH⁺; 522 = M - PhCO; 352 = M - TrOMe; 273 = MeOTr⁺; 240 = PhCONH-AdH⁺.

EXAMPLE 17

1 α -(N-Benzoyl-adenyl)-3 α -hydroxymethyl-3 β -methoxy-trityloxymethyl-cyclobutane 22:

Concentrated aqueous ammonia (200 ml) was added to a solution of 19 (200 mg, 0.274 mmole) in tetrahydrofuran (2 ml) and water (500 ml). This mixture was stirred at room temperature for 5 hours (TLC control: ethyl acetate/methanol = 8/2) and evaporated to dryness. The obtained oil was purified by flash chromatography (eluent:

ethyl acetate to ethyl acetate/methanol = 7/3) to afford 100 mg, 59 % of colourless crystals.

EXAMPLE 18

1 α -(N-Benzoyl-adenyl)-3 β -hydroxymethyl-3 α -methoxy-
5 trityloxymethyl-cyclobutane 23:

Analogous to the procedure for 22, 20 (200 mg, 0.274 mmole) afforded 23 (100 mg, 59 %) as colourless crystals.

EXAMPLE 19

1 α -Benzyloxy,3-bis-carboxy-cyclobutane 26:
10 4M aqueous potassium hydroxide (77.4 ml, 309.6 mmoles) was added to a solution of 4 (23.71 g, 77.39 mmoles) in water (57 ml) and ethanol (171 ml). The reaction mixture was stirred at reflux for 5 hours and evaporated to dryness. The residue (approximately 21 g)
15 was brought to p_H = 3 with 2M aqueous hydrochloric acid (approximately 160 ml). Ethyl acetate (150 ml) was added and the aqueous phase extracted 4 times with ethyl acetate (4 x 150 ml). The organic phase was dried over sodium sulfate and evaporated to dryness. The oily residue was
20 twice evaporated with toluene (2 x 100 ml), the diacid 26 crystallized; C₁₃H₁₄O₅; MW = 250.254, yellow crystals, MP = 160 - 162° C; I.R. (film): 3470, 2926, 2856, 1728, 1497, 1453; ¹H (DMSO at 200 MHz): d in PPM: 7.32 (s: 5 H_{ar}); 4.98 (s: COOH); 4.45 (s: CH₂, Bzl); 4.15 (quint: H₁); 2.75
25 (m: ABX, H_{2a} + H_{4a}); 2.45 (m: ABX, H_{2b} + H_{4b}); ¹³C (DMSO at 50 MHz): d in PPM: 176.10: CO; 175.60: CO; 139.78: C_r; 129.72: C_o; 129.66: C_m; 129.38: C_p; 71.49: C₁; 69.33: CH₂, Bzl; 47.25: C₃; 39.08: C₂ + C₄.

EXAMPLE 20

1 α -Benzyloxy-3 α -carboxy-cyclobutane 27 cis and 1 α -benzyloxy-3 β -carboxy-cyclobutane 27 trans:

The diacid 26 was decarboxylated in a kugelrohr distillation apparatus at 215° C and 0.4 Torr. A 1:1 mixture of the two monoacids 27 cis and 27 trans was obtained. At this stage both isomers could not be separated by flash chromatography (1 spot on TLC for both compounds: chloroform/methanol/water = 65/30/5): 27 cis + 27 trans: 14.69 g, 88.6 % starting from diester 4; C₁₄H₁₄O₂; MW: 214.265; I.R. (film): 3200, 2926, 2854, 2350, 1732, 1603, 1496, 1454; ¹H (CDCl₃ at 200 MHz): d in PPM: 11.40 (s: COOH); 7.35 (s: 5 H_{ar}); 4.45 (s: CH₂, Bzl); 4.35 (quint: H₁); 3.98 (quint: H₁); 3.10 (m: H₃); 2.68 (m: H₃); 2.55 (m: ABX, H_{2a} + H_{4a}); 2.35 (m: ABX, H_{2b} + H_{4b}); ¹³C (CDCl₃ at 50 MHz): d in PPM: 182.85: CO; 181.13: CO; 138.51: C_r; 138.45: C_r; 129.00: C_o; 128.45: C_m; 128.33: C_p; 71.78: C₁; 70.70: CH₂, Bzl; 70.52: CH₂, Bzl; 68.78: C₁; 34.24: C₂; 34.13: C₂; 33.60: C₄; 33.46: C₄; 31.95: C₃; 29.56: C₃.

EXAMPLE 21

1 α -Benzyloxy-cyclobutane-3 α -carboxylic acid chloride 28 cis and 1 α -benzyloxy-cyclobutane-3 β -carboxylic acid chloride 28 trans:

Neat oxalyl chloride (42.3 ml, 485 mmoles) was added slowly over 1 hour at 0° C to a solution of 27 cis + 27 trans (28.61g, 133.5 mmoles) in carbon tetrachloride (230 ml). The reaction started immediately with evolution of CO₂. The mixture was stirred 1 hour at 0° C and 12 hours at room temperature. This solution was evaporated to dryness to afford a 1:1 mixture of 28 cis + 28 trans: 31.13 g, 99.5 %; C₁₂H₁₃ClO₂; MW = 234.363; ¹H (CDCl₃ at 200 MHz): d in PPM: 7.35 (s: 5 H_{ar}); 4.48 (s: CH₂, Bzl); 4.42

(s: CH₂, Bzl); 4.22 (quint: H₁); 3.98 (quint: H₁); 3.55 (m: H₃); 3.08 (m: H₃); 2.68 (m: ABX, H_{2a} + H_{4a}); 2.35 (m: ABX, H_{2b} + H_{4b}); ¹³C (CDCl₃ at 50 MHz): d in PPM: 157.00: CO; 156.22: CO; 138.17: C_r; 138.14: C_r; 129.09: C_o; 128.79: C_o; 128.61: C_m; 128.52: C_m; 128.12: C_p; 70.93: C_i; 70.70: CH₂, Bzl; 67.72: C_i; 44.37: C₃; 41.86: C₃; 35.14: C₂; 34.08: C₄.

EXAMPLE 22

1α-Benzylloxy-3α-carbethoxy-cyclobutane 29 *cis* and 1α-benzylloxy-3β-carbethoxy-cyclobutane 29 *trans*:

The 1:1 mixture of the acid chlorides 28 *cis* and 28 *trans* (31.13 g, 132.8 mmoles) was twice evaporated in the presence of carbon tetrachloride (50 ml) and toluene (50 ml). Ethanol (100 ml) was slowly added at 0° C under argon to the solution of 28 *cis* and 28 *trans* in carbon tetrachloride (50 ml). The reaction mixture was stirred for 5 hours at room temperature (TLC control: tertio-butylmethylether/hexane = 2/8) and evaporated to dryness. The isomeric ethyl esters were separated by flash chromatography (eluent: tertio-butylmethylether/hexane = 2/8 to 8/2). The fraction containing both isomers was chromatographed a second time with the same solvent to give fraction 1: R_f = 0.28, compound 29 *trans*, 12.02 g, 38.4 % and fraction 2: R_f = 0.22, compound 29 *cis*, 11.94 g, 38.2 % starting from the mixture of monoacids 27 *cis* and 27 *trans*.

1α-Benzylloxy-3β-carbethoxy-cyclobutane 29 *trans*:

Fraction 1, MW = 234.296; IR (film): 2986, 2945, 1731, 1604, 1496, 1374, 1354; ¹H (CDCl₃ at 400 MHz): d in PPM: 7.35 (s: Ph); 4.48 (s: CH₂, Bzl); 4.32 (quint: H₁); 4.18 (q: CH₂, Et); 3.08 (tt: H₃); 2.55 (m: H_{2b} + H_{4b}); 2.35 (m: H_{2a} + H_{4a}); 1.35 (t: CH₃, Et); ¹³C (CDCl₃ at 100 MHz): d in PPM: 176.8: CO; 138.0: C_r Ph; 128.2: C_o Ph; 127.6: C_m

Ph; 127.5: C_P Ph; 71.5: C₁; 70.4: CH₂, Bzl; 60.2: CH₂, Et;
 33.4: C₂ + C₄; 32.0: C₃; 14.1: CH₃, Et; ¹H (CDCl₃ at 400
 MHz) NOE experiments: irradiation on H_{2b}: positive NOE on
 H₁ and no effect on H₃ and Et; irradiation on H_{2a}: posi-
 5 tive NOE on H₃, Et and no effect on H₁.

Anal. calculated for C₁₄H₁₈O₃ + 0.06 H₂O: C 71.44, H
 7.76, O 20.80; found: C 71.26, H 7.78, O 20.63.

1α-Benzylloxy-3α-carbethoxy-cyclobutane 29 cis:

Fraction 2; MW = 234.296; I.R. (film): 2986, 2943,
 10 2865, 1731, 1604, 1496, 1454; ¹H (CDCl₃ at 400 MHz): δ in
 PPM: 7.35 (s: Ph); 4.38 (s: CH₂, Bzl); 4.08 (q: CH₂, Et);
 3.86 (quint: H₁); 2.60 (m: H₃); 2.40 (m: H_{2b} + H_{4b}); 2.20
 (m: H_{2a} + H_{4a}); 1.32 (t: CH₃, Et); ¹³C (CDCl₃ at 100 MHz):
 δ in PPM: 174.38: CO; 138.02: C_r Ph; 128.32: C_o Ph;
 15 127.67: C_m Ph; 127.60: C_p Ph; 69.82: C₁; 68.28: CH₂, Bzl;
 60.29: CH₂, Et; 33.69: C₂ + C₄; 29.04: C₃; 13.88: CH₃, Et;
¹H (CDCl₃ at 400 MHz) NOE experiments: irradiation on H_{2b}:
 positive NOE on H₁ and H₃; irradiation on H_{2a}: no effect
 on H₃ and H₁.

20 Anal. calculated for C₁₄H₁₈O₃. 0.11 H₂O: C 71.17, H
 7.77, O 21.06; found: C 71.06, H 7.65, O 20.93.

EXAMPLE 23

1α-Benzylloxy-3α-carbethoxy-cyclobutane 29 cis and 1α-
 benzylloxy-3β-carbethoxy-cyclobutane 29 trans:

25 A solution of 4 (11.56 g, 37.76 mmoles), water (1.30
 ml, 75.52 mmoles) and sodium chloride (2.21 g, 37.76
 mmoles) in dimethylsulfoxide (19 ml) was heated at 210° C
 for 48 hours (TLC control: tertiobutylmethylether/hexane
 = 2/8). Three spots were visible on TLC: spot 1: Rf =
 30 0.28, 29 trans, spot 2: Rf = 0.22, 29 cis, spot 3: Rf =
 0.18, diester 4. Brine (150 ml) was added and the
 solution extracted 7 times with diethylether (7 x 100 ml),

which was dried over magnesium sulfate and evaporated to dryness. The mixture was separated by flash chromatography (eluent: tertibutylmethylether/hexane = 2/8 to 8/2). The fraction containing both isomers was chromatographed a second time with the same solvent to give fraction 1: Rf = 0.28, compound 29 trans, 3.34 g, 37.9 %; fraction 2: Rf = 0.22, compound 29 cis, 4.43 g, 50.1 %.

EXAMPLE 24

1 α -Benzyloxy-3 α -hydroxymethyl-cyclobutane 30 cis and
10 1 α -benzyloxy-3 β -hydroxymethyl-cyclobutane 30 trans:

Lithium aluminum hydride (1.39 g, 36.36 mmoles) was stirred under argon in dimethoxyethane (50 ml). The 1:1 mixture of the acids 27 cis and 27 trans (5.19 g, 24.21 mmoles) in dimethoxyethane (10 ml) was added dropwise
15 without cooling. The suspension was mechanically stirred at 85° C for 60 hours (TLC control: tertibutylmethylether/hexane = 9/1, only 1 spot was visible). After cooling, water (100 ml) was slowly added until the suspension turned from gray to white. This suspension was
20 evaporated to dryness, a mixture of tetrahydrofuran and ethyl acetate 9/1 (100 ml) was added and the suspension filtered over Hyflo. The precipitate was washed 3 times with the same solvent mixture (3 x 50 ml) and the obtained solution was evaporated to dryness. The 1:1 mixture of
25 the isomers was purified by flash chromatography (eluent: tertibutylmethylether/hexane = 1/1 to tertibutylmethylether) to afford 30 cis and 30 trans: 4.60 g, 98.8 %; MW = 192.258; ¹H (CDCl₃ at 200 MHz): d in PPM: 7.36 (s: Ph); 4.32 (s: CH₂, Bzl); 4.30 (s: CH₂, Bzl); 4.15 (quint: H₁); 3.85 (quint: H₁); 3.60 (d: CH₂OH); 2.33 (m: H_{2b} + H_{4b}); 2.08 (m: H_{2a} + H_{4a}); 1.90 (m: H₃); ¹³C (CDCl₃ at 50 MHz): d in PPM: 138.79: C_r Ph; 138.74: C_r Ph; 128.93: C_o Ph; 128.46: C_m Ph; 128.41: C_p Ph; 128.18: C_p Ph; 72.22: C₁;

GP 055981

SUBSTITUTE SHEET

69.85: C₁; 70.37: CH₂, Bzl; 67.36: CH₂OH; 66.85: CH₂OH;
32.25: C₂; 32.00: C₄; 30.01: C₃; 28.52: C₃.

Anal. calculated for C₁₂H₁₆O₂: C 74.97, H 8.39, O
16.64; found: C 75.00, H 8.40, O 16.69.

5 **EXAMPLE 25**

1α-Benzylloxy-3α-hydroxymethyl-cyclobutane 30 *cis*:

Lithium aluminum hydride (607 mg, 16.00 mmoles) was
stirred under argon in dimethoxyethane (50 ml). The ester
29 *cis* (5.13 g, 21.90 mmoles) was added neat dropwise
10 without cooling. The suspension was mechanically stirred
at 85° C for 60 hours (TLC control: tertibutylmethyl-
ether/hexane = 9/1). After cooling, water (100 ml) was
slowly added until the suspension turned from gray to
white. This suspension was evaporated to dryness, a
15 mixture of tetrahydrofuran and ethyl acetate 9/1 (100 ml)
was added and the obtained suspension filtered over Hyflo.
The precipitate was washed 3 times with the same solvent
mixture (3 x 50 ml) and the solution was evaporated to
dryness. The compound was purified by flash chromato-
20 graphy (eluent: tertibutylmethylether/hexane = 1/1 to
tertibutylmethylether) to afford 30 *cis*: 3.87 g, 91.9 %;
MW = 192.258; I.R. (film): 3398, 2974, 2991, 2933, 2861,
1951, 1878, 1612; ¹H (CDCl₃ at 200 MHz): d in PPM: 7.33
(s: Ph); 4.30 (s: CH₂, Bzl); 3.86 (quint: H₁); 3.60 (d:
25 CH₂OH); 2.33 (m: H_{2b} + H_{4b}); 2.08 (m: H_{2a} + H_{4a}); 1.90 (m:
H₃); ¹³C (CDCl₃ at 50 MHz): d in PPM: 138.72: C_r Ph;
128.93: C_o Ph; 128.42: C_m Ph; 128.14: C_p Ph; 69.85: C₁;
70.37: CH₂, Bzl; 66.85: CH₂OH; 32.25: C₂; 32.00: C₄; 28.52:
C₃.

30 Anal. calculated for C₁₂H₁₆O₂: C 74.97, H 8.39, O
16.64; found: C 75.00, H 8.40, O 16.69.

EXAMPLE 26

1- α -Benzyloxy-3 β -hydroxymethyl-cyclobutane 30 trans:

Analogous to the procedure for 30 cis, 29 trans (5.0 g, 21.34 mmoles) afforded 30 trans: 3.70 g, 90.2 %; MW =
5 192.258; I.R. (film): 3415, 3031, 2970, 2934, 2863, 1954,
1877, 1812; ^1H (CDCl_3 at 200 MHz): δ in PPM (J: Hz): 7.35
(s: Ph); 4.37 (s: CH_2 , Bzl); 4.12 (quint: J: 6.5, H_1);
3.59 (d: J:7.0, CH_2OH); 2.35 (m: H_3); 2.11 (m: $\text{H}_2 + \text{H}_4$);
 ^{13}C (CDCl_3 at 50 MHz): δ in PPM: 138.78: C_r Ph; 128.90: C_o
10 Ph; 128.36: C_m Ph; 128.12: C_p Ph; 72.15: C_1 ; 70.34: CH_2 ,
Bzl; 67.05: CH_2OH ; 31.99: $\text{C}_2 + \text{C}_4$; 29.96: C_3 .

Anal. calculated for $\text{C}_{12}\text{H}_{16}\text{O}_2$: C 74.97, H 8.39,
O 16.64; found: C 75.00, H 8.40, O 16.69.

EXAMPLE 27

15 1- α -Benzyloxy-3 α -tertbutyldiphenylsilyloxymethyl-
cyclobutane 31 cis:

Tertbutyldiphenylchlorosilane (16.39 ml, 63.00
mmoles) was added neat at 0°C under argon to a solution
of 30 cis (10.09 g, 52.49 mmoles) and imidazole (7.15 g,
20 105.0 mmoles) in dimethylformamide (250 ml). The reaction
mixture was stirred at room temperature for 20 hours (TLC
control: tertbutylmethylether/hexane = 5/95). Two spots
were visible on TLC: spot 1: 31 cis and spot 2: tertio-
butyldiphenylsilylhydroxyde. Water (250 ml) was added and
25 the solution extracted 3 times with ethyl acetate (3 x 300
ml). The combined organic phases were washed with water
(150 ml) and brine (150 ml), dried over magnesium sulfate
and evaporated to dryness. Flash chromatography (eluent:
tertbutylmethylether/hexane = 1/99 to 5/95) afforded 31
30 cis (18.50 g, 81.2 %) as a colourless oil; MW = 430.665;
I.R. (film): 3070, 3049, 2931, 2892, 2857, 1959, 1890,
1824, 1722, 1589, 1568; ^1H (CDCl_3 at 200 MHz): δ in PPM
(J: Hz): 7.68 (m: 4 H_{ar}); 7.36 (m: 11 H_{ar}); 4.42 (s: CH_2 ,

GP 055983

SUBSTITUTE SHEET

Bzl); 3.95 (quint: J: 6.0, H₁); 3.67 (d: J: 6.0, CH₂OSi);
 2.33 (q: H_{2a} + H_{4a}); 2.10 (m: H₃); 1.87 (t: H_{2b} - H_{4b});
 1.10 (s: CH₃, tBu); ¹³C (CDCl₃ at 50 MHz): d in PPM:
 139.04: C_r Ph; 136.18: C_o PhSi; 134.54: C_r PhSi; 130.10: C_p
 5 PhSi; 128.89: C_o Ph; 128.40: C_m Ph; 123.17: C_m PhSi; 128.07:
 C_p Ph; 70.19: CH₂, Bzl; 69.87: C₁; 67.94: CH₂OSi; 33.16: C₂
 + C₄; 28.53: C₃; 27.21: CH₃, tBu; 19.64: C, tBu; U.V.
 (methanol, 0.5 x 10⁻⁴ mole/l): 1 max in nm (ε max): 259
 (840); 265 (920).

10 Anal. calculated for C₂₈H₃₄O₂Si: C 78.09, H 7.96, Si
 6.52, O 7.43; found: C 78.02, H 8.18, Si 6.67.

EXAMPLE 28

1α-Benzylloxy-3β-tertiobutyldiphenylsilyloxymethyl-
 cyclobutane 31 trans:

15 Tertibutyldiphenylchlorosilane (3.24 ml, 12.48
 mmoles) was added neat at 0° C under argon to a solution
 of 30 trans (2 g, 10.40 mmoles) and imidazole (1.42 g,
 20.80 mmoles) in dimethylformamide (80 ml). The reaction
 mixture was stirred at room temperature for 64 hours (TLC
 20 control: tertibutylmethylether/hexane = 5/95). Two spots
 were visible on TLC: spot 1: 31 trans and spot 2: tertic-
 butyldiphenylsilylhydroxyde. Ethyl acetate (200 ml) and
 water (50 ml) were added and the aqueous phase extracted
 twice with ethyl acetate (2 x 200 ml). The combined
 25 organic phases were washed twice with brine (2 x 50 ml),
 dried over magnesium sulfate and evaporated to dryness.
 Flash chromatography (eluent: tertibutylmethylether/hex-
 ane = 1/99 to 5/95) afforded 31 trans (4.40 g, 98.2 %) as
 a colourless oil; MW = 430.665; I.R. (film): 3071, 3050,
 3032, 2932, 2892, 2857, 1958, 1889, 1821, 1721, 1589; ¹H
 30 (CDCl₃ at 200 MHz): d in PPM (J: Hz): 7.68 (m: 4 H_{ar});
 7.50 -> 7.30 (m: 11 H_{ar}); 4.38 (s: CH₂, Bzl); 4.17 (quint:
 J: 6.0, H₁); 3.67 (d: J: 6.0, CH₂OSi); 2.42 (m: H₃); 2.15

(m: $H_2 + H_4$); 1.05 (s: CH_3 , tBu); ^{13}C ($CDCl_3$ at 50 MHz):
 d in PPM: 138.50: $C_{r\text{ Ph}}$; 136.18: $C_{o\text{ PhSi}}$; 133.04: $C_{r\text{ PhSi}}$;
 130.13: $C_{p\text{ PhSi}}$; 128.90: $C_{o\text{ Ph}}$; 128.39: $C_{m\text{ Ph}}$; 128.17: $C_{e\text{ PhSi}}$;
 128.07: $C_{p\text{ Ph}}$; 72.08: C_1 ; 70.30: CH_2 , Bzl; 67.43:
 5 CH_2OSi ; 32.11: $C_2 + C_4$; 30.06: C_3 ; 27.18: CH_3 , tBu; 19.58:
 C, tBu; U.V. (methanol, 0.5×10^{-4} mole/l): 1 max in nm (e
 max): 253 (800); 259 (960); 264 (760); 270 (640).

Anal. calculated for $C_{28}H_{34}O_2Si$: C 78.09, H 7.96, Si
 6.52, O 7.43; found: C 77.80, H 7.95, Si 6.48.

10 EXAMPLE 29

1 α -Hydroxy-3 α -tertiobutyldiphenylsilyloxymethyl-
cyclobutane 32 cis:

Degussa palladium (500 mg) in dimethoxyethane (250
 ml) was first placed under a hydrogen atmosphere. 31 cis
 15 (10 g, 23.27 mmoles) was then added neat. The reaction
 mixture was shaken vigorously at room temperature under
 a hydrogen pressure of 1 atmosphere until 1 equivalent of
 hydrogen (209 ml) was absorbed (approximately 8 hours).
 After filtration of the catalyst over Hyflo, the solution
 20 was evaporated to dryness to afford 32 cis as a colourless
 syrup (7.80 g, 99.2 %); MW = 340.54; (tertiobutylmethyl-
 ether/hexane = 2/8), Rf = 0.11; I.R. (film): 3342, 3135,
 3071, 3050, 2929, 2893, 2856, 1959, 1888, 1824, 1776,
 1741; 1H ($CDCl_3$ at 200 MHz): d in PPM (J: Hz): 7.70 (dd:
 25 4 H_{ar}); 7.40 (s: $C_{p\text{ PhSi}}$); 7.30 (dd: 4 H_{ar}); 4.27 (quint:
 J: 7.0, H_1); 3.67 (d: J: 7.0, CH_2OSi); 2.30 (m: ABX $H_{2a} +$
 H_{4a}); 2.20 (m: H_3); 1.95 (m: ABX $H_{2b} + H_{4b}$); 1.10 (s: CH_3 ,
 tBu); U.V. (methanol, 0.5×10^{-4} mole/l): 1 max in nm (e
 max): 259 (600); 264 (640); 270 (440).

30 Anal. calculated for $C_{21}H_{28}C_2Si$: C 74.07, H 8.29, Si
 8.25, O 9.39; found: C 74.29, H 8.12, Si 8.33.

EXAMPLE 30

1 α -Hydroxy-3 β -tertbutyldiphenylsilyloxymethyl-cyclobutane 32 trans:

Analogous to the procedure for 32 cis, 31 trans (10
 5 g, 23.27 mmoles) afforded 32 trans as a colourless syrup
 (7.95 g, 99.7 %); MW = 340.54; (tertbutylmethylether/hexane = 2/8), R_f = 0.11; I.R. (film): 3070, 3050,
 2960, 2920, 2850, 1960, 1890, 1820, 1770, 1740; ¹H (CDCl₃
 at 200 MHz): δ in PPM (J: Hz): 7.70 (dd: 4 H_{ar}); 7.45 (s:
 10 C_p PhSi); 7.40 (dd: 4 H_{ar}); 4.47 (quint: J: 7.0, H₁); 3.67
 (δ : J: 7.0, CH₂OSi); 2.44 (m: H₃); 2.25 (m: ABX H_{2a} + H_{4a});
 2.05 (m: ABX H_{2b} + H_{4b}); 1.10 (s: CH₃, tBu); ¹³C (CDCl₃ at
 50 MHz): δ in PPM: 136.16: C_o PhSi; 134.32: C_r PhSi;
 130.18: C_p PhSi; 128.16: C_m PhSi; 67.31: CH₂OSi; 66.72: C₁;
 15 35.26: C₂ + C₄; 29.36: C₃; 27.15: CH₃, tBu; 19.58: C, tBu;
 U.V. (methanol, 0.5 x 10⁻⁴ mole/l): λ max in nm (ϵ max) :
 259 (760); 264 (800); 270 (560).

Anal. calculated for C₂₁H₂₈O₂Si: C 74.07, H 8.29, Si
 8.25, O 9.39; found: C 74.06, H 8.21, Si 7.99.

20 EXAMPLE 31

1 α -p-Bromo-benzenesulfonyloxy-3 α -tertbutyldiphenyl-
 silyloxymethyl-cyclobutane 33 cis:

p-Bromo-benzenesulfonylchloride (3.02 g, 11.82
 mmoles) was added neat at room temperature under argon to
 25 a solution of 32 cis (3.35 g, 9.85 mmoles) and triethyl-
 amine (9.60 ml, 68.96 mmoles) in dichloromethane (50 ml).
 The reaction mixture was stirred at room temperature for
 15 hours (TLC control: tertbutylmethylether/hexane =
 2/8: R_f = 0.40). On TLC no more alcohol was visible.
 30 Brine (50 ml) was added and the reaction mixture extracted
 3 times with ethyl acetate (3 x 200 ml). The combined
 organic fractions were washed with brine (50 ml), dried
 over sodium sulfate and evaporated to dryness. Flash

chromatography (eluent: tertibutylmethylether/hexane = 5/95 to 1/9) afforded 33 cis: 4.20 g, 76.2 %; MW = 559.598; (tertiobutylmethylether/hexane = 2/8), Rf = 0.40; MP = 83.5 - 84.5° C after crystallization from diethyl-
 5 ether; I.R. (film): 3071, 2931, 2893, 2857, 1576, 1471;
¹H (CDCl₃ at 200 MHz): d in PPM (J: Hz): 7.80 -> 7.60 (m: 8 H_{ar}); 7.45 -> 7.32 (m: 6 H_{ar}); 4.70 (quint: J: 7.0, H₁); 3.52 (d: J: 7.0, CH₂OSi); 2.30 -> 1.95 (m: H₂ + H₃ + H₄); 1.05 (s: CH₃, tBu); ¹³C (CDCl₃ at 50 MHz): d in PPM:-
 10 136.50: C_r Brs ; 136.10: C_o PhSi; 134.06: C_r PhSi; 133.08: C_m Brs; 130.24: C_p PhSi; 129.81: C_o Brs; 129.20: C_p Brs; 128.22: C_m PhSi; 72.39: C₁; 65.85: CH₂OSi; 32.85: C₂ + C₄; 28.81: C₃; 27.13: CH₃, tBu; 19.59: C, tBu; U.V. (methanol, 0.5 x 10⁻⁴ mole/l): λ max in nm (ε max): 221 (23400); 256
 15 (1200); 263 (1300).

Anal. calculated for C₂₇H₃₁BrO₃SSi: C 57.95, H 5.58, Br 14.28, S 5.73, Si 5.02; found: C 57.73, H 5.63, Br 14.11, S 5.67, Si 4.85.

EXAMPLE 32

20 1α-p-Bromo-benzenesulfonyloxy-3β-tertiobutyldiphenylsilyloxymethyl-cyclobutane 33 trans:

p-Bromo-benzenesulfonylchloride (2.08 g, 8.14 mmoles) was added neat at room temperature under argon to a solution of 32 trans (2.31 g, 6.78 mmoles) and triethyl-
 25 amine (6.61 ml, 47.48 mmoles) in dichloromethane (50 ml). The reaction mixture was stirred at room temperature for 36 hours (TLC control: tertibutylmethylether/hexane = 2/8: Rf: 0.40). Another two portions of p-bromo-benzenesulfonylchloride (2 x 200 mg, 2 x 0.81 mmoles) were added.
 30 On TLC no more alcohol was visible. Brine (30 ml) was added and the reaction mixture extracted 3 times with ethyl acetate (3 x 200 ml). The combined organic fractions were washed with brine (50 ml), dried over

sodium sulfate and evaporated to dryness to afford 33
 trans: 3.04 g, 80.1 %; MW: 559.598; (tertbutylmethyl-
 ether/hexane: = 2/8), R_f = 0.40; MP = 60 - 81° C after
 crystallization from diethylether; I.R. (film): 3070,
 5 2940, 2880, 2860, 1580, 1470; ¹H (CDCl₃ at 200 MHz): d in
 PPM (J: Hz): 7.80 -> 7.60 (m: 8 H_{ar}); 7.45 -> 7.32 (m: 6
 H_{ar}); 4.98 (quint: J: 7.0, H₁); 3.58 (d: J: 7.0, CH₂OSi);
 2.30 (m: H₂ + H₃ + H₄); 1.05 (s: CH₃, tBu); ¹³C (CDCl₃ at
 50 MHz): d in PPM: 136.51: C_r Brs; 136.13: C_o PhSi; 134.02:
 10 C_r PhSi; 133.08: C_m Brs; 131.12: C_o Brs; 130.51: C_p PhSi;
 129.20: C_p Brs; 128.20: C_m PhSi; 75.46: C₁; 65.92: CH₂OSi;
 32.90: C₂ + C₄; 30.15: C₃; 27.16: CH₃, tBu; 19.56: C, tBu;
 U.V. (methanol, 0.5 x 10⁻⁴ mole/l): 1 max in nm (ε max):
 220 (23060); 233 (16500); 259 (1300); 259 (1300); 265
 15 (1400).

Anal. calculated for C₂₇H₃₁BrO₄ SSi: C 57.95, H 5.58,
 Br 14.28, S 5.73, Si 5.02; found: C 57.96, H 5.69, Br
 14.00, S 5.61, Si 4.85.

EXAMPLE 33

20 1α-Adenyl(9)-3α-tertbutyldiphenylsilyloxymethyl-
 cyclobutane 34 cis and 1α-adenyl(7)-3α-tertbutyldiphenyl-
 silyloxymethyl-cyclobutane 35 cis:

A mixture of 33 trans (2.78 g, 4.96 mmoles), adenine
 (19.84 g, 26.82 mmoles) and diazabicycloundecene (3.02
 25 ml, 2.96 mmoles) in dimethylsulfoxide (28 ml) were stirred
 under argon at 80° C for 15 hours (TLC control: tertio-
 butylmethylether/methanol = 8/2; detection: 1) chlorine
 2) potassium iodide). Three spots were visible on TLC:
 spot 1: R_f = 0.95, unreacted 33 trans; spot 2: R_f = 0.88,
 30 compound 34 cis; spot 3: R_f = 0.57, compound 35 cis.
 Brine (200 ml) and water (800 ml) were added and the
 solution was extracted 7 times with ethyl acetate (4 x 75
 ml). The combined organic fractions were washed with

brine (50 ml), dried over sodium sulfate and purified by flash chromatography (tertbutylmethylether/methanol = 98/2 to 1/1) to afford fraction 1: compound 33 trans, 735 mg, 26.0 %; fraction 2: compound 34 cis, 1.06 g, 46.8 %; fraction 3: compound 35 cis, 190 mg, 8.4 %.

1 α -Adenyl(9)-3 α -tertiobutyldiphenylsilyloxymethylcyclobutane 34 cis:

Fraction 2; MW = 457.65; MP = 181 - 182° C; I.R. (KBr): 3324, 3160, 2929, 2855, 1662, 1601, 1571; ¹H (CDCl₃ at 200 MHz): δ in PPM: 8.35 (s: H_{2ad}); 7.88 (s: H_{8ad}); 7.67 (m: 4 H_{ar}); 7.37 (m: 6 H_{ar}); 5.98 (s: NH₂); 4.92 (quint: H₁); 3.22 (s: CH₂OSi); 2.65 -> 2.35 (m: H₂ + H₃ + H₄); 1.10 (s: CH₃, tBu); ¹³C (CDCl₃ at 50 MHz): δ in PPM: 156.11: C_{6ad}; 153.46: C_{2ad}; 152.05: C_{4ad}; 139.16: C_{8ad}; 136.16: C_o PhSi; 134.07: C_r PhSi; 130.21: C_p PhSi; 128.27: C_m PhSi; 118.43: C_{5ad}; 65.85: CH₂OSi; 45.13: C₁; 32.61 C₂ + C₄; 30.82: C₃; 27.21: CH₃, tBu; 19.62: C, tBu; U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max): 204 (34780); 258 (12920).

Anal. calculated for C₂₆H₃₁N₅OSi: C 68.24, H 6.83, N 15.30, Si 6.14; found: C 68.09, H 6.84, N 15.43, Si 6.18.

1 α -Adenyl(7)-3 α -tertiobutyldiphenylsilyloxymethylcyclobutane 35 cis:

Fraction 3, C₂₆H₃₁N₅OSi, MW = 457.65, I.R. (KBr): 3071, 2931, 2857, 1922, 1895, 1870, 1844, 1800, 1773, 1751, 1654, 1619, 1578; ¹H (CDCl₃ at 200 MHz): δ in PPM: 8.10 (s: H_{2ad}); 8.02 (s: H_{8ad}); 7.65 (m: 4 H_{ar}); 7.37 (m: 6 H_{ar}); 5.12 (quint: H₁); 3.71 (s: CH₂OSi); 2.70 (m: H_{2a} + H_{4a}); 2.45 (m: H_{2b} + H₃ + H_{4b}); 1.05 (s: CH₃, tBu); U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max) : 214 (29800); 277 (16280).

EXAMPLE 34

1 α -Adenyl(9)-3 β -tertiobutyldiphenylsilyloxymethyl-cyclobutane 34 trans and 1 α -adenyl(7)-3 β -tertiobutyldiphenylsilyloxymethyl-cyclobutane 35 trans:

- 5 A mixture of 33 cis (3.81 g, 6.81 mmoles), adenine (3.68 g, 27.22 mmoles) and diazabicycloundecene (4.05 ml, 4.14 mmoles) in dimethylsulfoxide (38 ml) were stirred under argon at 80° C for 35 hours (TLC control: tertio-
- 10 butylmethylether/methanol = 8/2; detection: 1) chlorine 2) potassium iodide). Two spots were visible on TLC: spot 1: Rf = 0.95, unreacted 33 cis; spot 2: Rf = 0.88, compound 34 trans; spot 3: Rf = 0.57, compound 35 trans. Brine (200 ml), water (800 ml) were added and the solution was extracted 7 times with ethyl acetate (4 x 75 ml). The
- 15 collected organic fractions were washed with brine (50 ml), dried over sodium sulfate and purified by flash chromatography (tertiobutylmethylether/methanol = 98/2 to 1/1) to afford fraction 1: compound 33 cis, 1.29 g, 33.9 %; fraction 2: compound 34 trans, 1.46 g, 46.9 %; fraction
- 20 3: compound 35 trans, 401 mg, 12.9 %.

1 α -Adenyl(9)-3 β -tertiobutyldiphenylsilyloxymethyl-cyclobutane 34 trans:

- Fraction 2; MW = 457.65; MP = 129.5 - 130.5° C; I.R. (KBr): 3138, 2929, 2857, 1660, 1651, 1645, 1650, 1600,
- 25 1574; ¹H (CDCl₃ at 200 MHz): d in PPM: 8.35 (s: H_{2ad}); 7.90 (s: H_{8ad}); 7.67 (m: 4 H_{ar}); 7.37 (m: 6 H_{ar}); 6.78 (s: NH₂); 5.10 (quint: H₁); 3.77 (s: CH₂OSi); 2.60 -> 2.45 (m: H₂ + H₃ + H₄); 1.10 (s: CH₃, tBu); ¹³C (CDCl₃ at 50 MHz): d in PPM: 156.98: C_{6ad}; 153.34: C_{2ad}; 150.53: C_{4ad}; 139.28 C_{8ad};
- 30 136.16: C_o PhSi; 134.14: C_r PhSi; 130.30: C_p PhSi; 128.29: C_m PhSi; 120.43: C_{5ad}; 66.54: CH₂OSi; 47.98: C₁; 31.82: C₂ + C₄; 31.48: C₃; 27.23: CH₃, tBu; 19.60: C, tBu; U.V. (water, 0.5 x 10⁻⁴ mole/l): 1 max in nm (e max): 205 (40000); 258 (13940).

Anal. calculated for $C_{26}H_{31}N_5OSi$: C 68.24, H 6.82, N 15.30, Si 6.14; found: C 68.45, H 7.07, N 14.95, Si 5.93.

1 α -Adenyl(7)-3 β -tertbutyldiphenylsilyloxymethyl-cyclobutane 35 *trans*:

5 Fraction 3, $C_{26}H_{31}N_5OSi$, MW = 457.65; I.R. (KBr): 3322, 2933, 2894, 2857, 2244, 2218, 1658, 1618, 1549; 1H (CDCl₃ at 200 MHz): δ in PPM: 8.10 (s: H_{2ad}); 8.02 (s: H_{8ad}); 7.65 (m: 4 H_{ar}); 7.37 (m: 6 H_{ar}); 5.22 (quint: H₁); 3.81 (s: CH₂OSi); 2.87 (m: H_{2a} + H_{4a}); 2.60 (m: H_{2b} + H₃ + 10 H_{4b}); 1.05 (s: CH₃, tBu); U.V. (water, 0.5 x 10⁻⁴ mole/l): λ max in nm (ϵ max): 214 (29800); 265 (9500).

EXAMPLE 35

1 α -Adenyl(9)-3 α -hydroxymethyl-cyclobutane 36 *cis*:

A solution of 34 *cis* (500 mg, 1.09 mmole) and aqueous 15 hydrofluoric acid - urea (3 ml, 9 mmoles) in tetrahydrofuran (10 ml) was stirred for 15 hours at room temperature (TLC control: ethyl acetate/methanol = 2/8; R_f = 0.12). The reaction mixture was neutralized with sodium bicarbonate and evaporated to dryness. Purification by flash 20 chromatography (ethyl acetate/methanol = 9/1) afforded a mixture of 36 *cis* and sodium fluoride. Flash chromatography on hydrophobic silica gel first with water gave sodium fluoride and then with methanol gave 36 *cis*: 60 mg as a glassy solid; 1H (CD₃OD at 200 MHz): δ in PPM: 8.22 25 (s: H_{2ad}); 8.18 (s: H_{8ad}); 4.95 (quint: H₁); 3.62 (s: CH₂OH); 2.55 (m: H_{2a} + H_{4a}); 2.40 (m: H_{2b} + H₃ + H_{4b}); ^{13}C (CD₃OD at 50 MHz): δ in PPM: 157.20: C_{6ad}; 153.92: C_{2ad}; 149.10: C_{4ad}; 141.22: C_{8ad}; 111.60: C_{5ad}; 66.05: CH₂OH; 46.73: C₁; 35.57: C₂ + C₄; 31.84: C₃; U.V. (ethanol, 0.5 30 x 10⁻⁴ mole/l): λ max in nm (ϵ max): 206 (16580); 262 (11160); C₁₀H₁₃N₂O₃; MW = 219.246; FAB-MS: M + Na = 242; M + H⁺ = 220; M - CH₃OH = 188; Ad + H⁺ = 136.

EXAMPLE 36

1 α -Adenyl(9)-3 β -hydroxymethyl-cyclobutane 36 trans:
Analogous to the procedure for 36 cis, 34 trans (500
mg, 1.09 mmole) afforded 36 trans, 60 mg, as a glassy
5 solid; ¹H (CD₃OD at 200 MHz): δ in PPM: 8.25 (s: H_{2ad});
8.16 (s: H_{8ad}); 5.15 (quint: H₁); 3.62 (s: CH₂OH); 2.60 (m:
H_{2a} + H_{4a}); 2.45 (m: H_{2b} + H₃ + H_{4b}); ¹³C (CD₃OD at 50 MHz):
 δ in PPM: 157.3 C_{6ad}; 153.90: C_{2ad}; 149.20: C_{4ad}; 141.44:
C_{8ad}; 112.40: C_{5ad}; 66.21: CH₂OH; 48.5: C₁; 35.75: C₂ + C₄;
10 31.80: C₃; U.V. (ethanol, 0.5 x 10⁻⁴ mole/l): 1 max in nm
(e max): 206 (16250); 262 (11050); C₁₀H₁₃N₂O₃; MW =
219.246; FAB-MS: M + Na = 242; M + H⁺ = 220; M - CH₃OH =
188; Ad + H⁺ = 136.

EXAMPLE 37

15 *Synthesis of Oligonucleotide Surrogates - Phospho-
triester Method*

1. Phosphorylation:

A typical activated phosphoryl compound was prepared
as follows: 1 α -(N-Benzoyl-adenyl)-3 α -hydroxymethyl-3 β -
20 methoxytrityloxymethyl-cyclobutane 22 (0.25 mmole, 156.4
mg) was co-evaporated with pyridine to remove traces of
water and phosphorylated with 2-chlorophenyl-di-(1-
benzotriazolyl)-phosphate (1.00 ml, 0.25 M) in THF at
room temperature for 30 min (activated nucleotide) as per:
25 Van Boom, J.H., Van der Marel, G.A., Van Boeckel, C.A.A.,
Wille, G. and Hoyng, C. *Chemical and Enzymatic Synthesis
of Gene Fragments*, A Laboratory Manual, edited by H.G.
Gassen and Anne Lang, Verlag Chemie Weinheim/Deerfield
Beach, Florida/Basel 1982. This intermediate, which can
30 be kept in solution for several hours, was further
processed in-situ.

In a like manner the corresponding guanine, cytosine,
uridine and thymine compounds are prepared.

2. Assembling of the nucleotides on a solid-phase:

11.5 mg of 3'-(MeOTr-adenosine(Bz))-succinylamido-methyl-polystyrene (1% DVB crosslinked) (functionalization = 2.24 mmoles), see Ito, H., Ike, Y., Ikuta, S. and Itakura, K. (1982) *Nucleic Acids Research*, 10:1755, was subjected to the following washing (3 ml/min) and reaction procedures: (dichloromethane-isopropanol = 85:15) (3 min), MeOTr-cleavage: 1 M ZnBr₂, 0.02 M 1,2,4-triazole in dichloromethane-isopropanol (85:15) (1.5-2 min), see Rink, H., Liersch, M., Sieber, P. and Meyer, F. (1984) *Nucleic Acids Research*, 12:6369, dichloromethane-isopropanol (85:15) (3 min), 0.5 M triethylammonium-acetate in DMF (3 min), acetonitrile (< 0.005 % water) (3 min), nitrogen flow 50° C (10 min).

15 Coupling: 64 ml activated carbanucleotide (16 mmol) and 6.4 ml N-methylimidazole (80 mMol), 12-15 min, 50° C, no flow, acetonitrile (4 min).

This solid-phase process was repeated seven times. Yield per coupling step: 80 - 87 %, i.e., 0.6 μmol or 46 OD units calculated yield.

25 The oligomer was cleaved from the carrier and the protecting groups removed by sequentially reacting the resin with 1 M tetramethylguanidinium 2-nitrobenzaldehyde oximate in 200 ml 95% pyridine during 7 h at 60° C and 0.8 ml 33% aqueous ammonia for 24 h at 60° C. The reaction mixture was extracted 3 times with diethylether (2 ml each) and the aqueous phase was applied to a Biogel P4 (50-100 mesh) column (3 x 26 cm) and the product eluted with water. Fractions were checked for correct size of the oligomer and homogeneity with polyacrylamide- or capillary-electrophoresis. No further purification was usually needed, however in view of the coupling yields with 22, additional fractionation was performed on a Mono Q HR5/5 anion-exchanger. The applied gradient was: A =

10 mM NaOH, 0.05 M NaCl; B = 10 mM NaOH, 2 M NaCl; C% B
-> 40% B linear in 45 min. Fractions homogeneous in
electrophoresis were checked with electrospray ionization
mass spectrometry for the presence of the expected
5 oligomer and were appropriately pooled and desalted on a
Biogel P4 column. 10 ODs (optical units 259 nm) of
octamer 24 and 7 ODs of the heptamer were isolated.

EXAMPLE 38

Synthesis of Oligonucleotide Surrogates - Phosphor-
10 *amidate Method*

1. Phosphoramidation:

A typical activated phosphoramidate is prepared as
follows: 1 α -(N-Benzoyladenyl)-3 β -hydroxymethyl-3 α -methoxy-
trityloxymethyl-cyclobutane 23 (1.89 mmol) is dissolved
15 in anhydrous dichloromethane (13 ml) under an argon atmo-
sphere, diisopropylethylamine (0.82 ml, 4.66 mmol) is
added, and the reaction mixture cooled to ice temperature.
Chloro(diisopropylamino)- β -cyanoethoxyphosphine (0.88 ml,
4.03 mmol) is added to the reaction mixture and the
20 reaction mixture is then allowed to warm to 20°C and
stirred for 3 hours. Ethylacetate (80 ml) and triethyl-
amine (1 ml) are added and the solution is washed with
brine solution three times (3 x 25 ml). The organic phase
is separated and dried over magnesium sulfate. After
25 filtration of the solids the solvent is evaporated in
vacuo at 20° C to an oil that is then purified by column
chromatography using silica and a solvent such as hexane-
ethyl acetate-triethylamine (50:49:1) as eluent. The
fractions are then evaporated in vacuo and the residue
30 further evaporated with anhydrous pyridine (20 ml) in
vacuo (1 torr) at 26° C in the presence of sodium
hydroxide for 24 hr. This will yield 1 α -(N-Benzoyl-
adenyl)-3 β -(β -cyanoethyl-diisopropylphosphorotityl)oxy-
methyl-3 α -methoxytrityloxymethyl-cyclobutane.

In a like manner the corresponding guanine, cytosine, uridine and thymine compounds are prepared.

2. *Assembly of Oligonucleotide Surrogates Using Standard Phosphoramidate Oligonucleotide Surrogate*
5 *Synthesis*

Phosphoramidate oligonucleotide surrogates synthesis are performed on an Applied Biosystems 380 B or 394 DNA synthesizer following standard phosphoramidate protocols and cycles. The oligonucleotide subunits are as described
10 above and all other reagents are as supplied by the manufacture. In those steps wherein phosphoramidites subunits of the oligonucleotide surrogates of the invention are used, a longer coupling time (10-15 min) is employed. The oligonucleotide surrogates are normally synthesized
15 in either a 10 μmol scale or a 3 x 1 μmol scale in the "Trityl-On" mode. Standard deprotection conditions (30% NH_4OH , 55°C, 16 hr) are employed. HPLC is performed on a Waters 600E instrument equipped with a model 991 detector. For analytical chromatography, the following reverse phase
20 HPLC conditions are employed: Hamilton PRP-1 column (15 x 2.5 cm); solvent A: 50mm TEAA, pH 7.0; solvent B: 45mm TEAA with 80% CH_3CN ; flow rate: 1.5ml/min; gradient: 5% B for the first 5 minutes, linear (1%) increase in B every minute thereafter. For preparative purposes, the following
25 reverse phase HPLC conditions are employed: Waters Delta Pak Waters Delta-Pak C₄, 15 μm , 300A, 25x100 mm column equipped with a guard column of the same material; column flow rate: 5ml/min; gradient: 5% B for the first 10 minutes, linear 1% increase for every minute there-
30 after. Following HPLC purification, the oligonucleotide surrogates are detritylated and further purified by size exclusion using a Sephadex G-25 column.

3. *Assembly of Phosphorothioate Oligonucleotide Surrogates Using Standard Phosphoramidate Oligonucleotide Surrogate Synthesis*

In a manner as per Example 38-2, the oligonucleotide surrogate is treated with the Beaucage reagent, i.e. 3H-1,2-benzodithioate-3-one 1,1-dioxide, see Radhakrishnan, P.I., Egan, W., Regan, J.B. and Beaucage, S.L., (1990), *J. Am. Chem. Soc.*, 112:1253 for conversion of the phosphodiester linkages to phosphorothioate linkages.

10 **EVALUATION**

PROCEDURE 1 - Hybridization Analysis.

As with an oligonucleotide, the relative ability of an oligonucleotide surrogate of the invention to bind to complementary nucleic acids can be compared by determining the melting temperature of a particular hybridization complex. The melting temperature (T_m), a characteristic physical property of double-stranded RNA or DNA, denotes the temperature in degrees centigrade at which 50% helical versus coil (unhybridized) forms are present. T_m is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher T_m . The higher the T_m , the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the T_m . Consequently, absolute fidelity of base pairing is necessary to have optimal binding of an antisense oligonucleotide to its targeted RNA or DNA.

A. Evaluation of the thermodynamics of hybridization of oligonucleotide surrogates.

The ability of the oligonucleotide surrogates of the invention to hybridize to their complementary RNA or DNA

sequences was determined by thermal melting analysis. The RNA complements used were poly-rA and poly-rU. The DNA complements used were poly-dA and (dT)₈. Additionally oligonucleotide surrogates of the invention were hybrid-
5 ized against one another and the T_ms determined. The oligonucleotide surrogates were added to either the RNA or DNA complement at stoichiometric concentrations and the absorbance (260 nm) hyperchromicity upon duplex to random coil transition was monitored using a Gilford Response II
10 spectrophotometer. Such measurements are performed in a buffer of 10 mM Na-phosphate, pH 7.4, 0.1 mM EDTA, and 1M NaCl. The data was analyzed by a graphic representation of 1/T_m vs ln[Ct], where [Ct] is the total oligonucleotide concentration.

15 The results of the thermodynamic analysis is shown in Tables 1 and 2. In both tables both measured T_ms and the percent hyperchromicity are shown. Table 1 shows results against other "normal" nucleic acid strands (that is ribofuranosyl or deoxy-ribofuranosyl based nucleic acid
20 strands) and Table 2 shows results against complementary cyclobutane strands - that is against one another.

For these tables pseudo βA refers to an 8 mer oligonucleotide surrogate of the invention formed from eight cyclobutane units wherein the adenine base is cis
25 to the methoxytrityloxymethyl moiety, i.e. compound 22, 1-α(N-benzoyl-adenyl)-3α-hydroxymethyl-3β-methoxytrityloxymethyl-cyclobutane. Pseudo αA refers to the corresponding 8 mer having the respective substituents of the cyclobutane ring trans to each other. In a like manner
30 pseudo βT and pseudo αT reference the corresponding 8 mer cis and trans thymine base oligonucleotide surrogates.

- 68 -

TABLE 1
Melting Temperature, T_m , and % Hyperchromicity of
The Hybridization Complex Of The Oligonucleotide
Surrogate and Complementary Nucleic Acid Strands

5

T_m and
(% Hyperchromicity)

Oligomer	Complementary Strand		
	poly-rA	poly-dA	poly-rU (dT) ₈
pseudo β A			9° (16%)
pseudo α A			28° (25%)
			55° (42%)
pseudo β T	11° (23%)	27° (24%)	20° (28%)
pseudo α T		10° (10%)	

10

15

25

TABLE 2

Melting Temperature, T_m , and % Hyperchromicity of
The Hybridization Complex Of The Oligonucleotide
Surrogates With One Another

T_m and
(% Hyperchromicity)

Oligomer	Complementary Strand	
	pseudo β T	pseudo α T
pseudo β A	20° (28%)	
pseudo α A	18° (28%)	12° (16%)

30

Page missing at the time of publication

adult human serum. Labeled oligonucleotide surrogates are incubated for various times, treated with protease K and then analyzed by gel electrophoresis on 20% polyacrylamide-urea denaturing gels and subsequent autoradiography. 5 Autoradiograms are quantitated by laser densitometry. Based upon the location of the modified linkage and the known length of the oligonucleotide surrogate, it is possible to determine the effect on nuclease degradation by the particular modification. For the cytoplasmic 10 nucleases, an HL 60 cell line can be used. A post-mitochondrial supernatant is prepared by differential centrifugation and the labelled oligonucleotide surrogates are incubated in this supernatant for various times. Following the incubation, the oligonucleotide surrogates 15 are assessed for degradation as outlined above for serum nucleolytic degradation. Autoradiography results are quantitated for comparison of the unmodified and the oligonucleotide surrogates of the invention. It is expected that the of oligonucleotide surrogates will be 20 completely resistant to serum and cytoplasmic nucleases.

B. Evaluation of the resistance of oligonucleotide surrogates to specific endo- and exo-nucleases.

Evaluation of the resistance of natural oligonucleotides and oligonucleotide surrogates of the invention to 25 specific nucleases (ie, endonucleases, 3',5'-exo-, and 5',3'-exonucleases) can be done to determine the exact effect of the modified linkage on degradation. The oligonucleotide surrogates are incubated in defined reaction buffers specific for various selected nucleases. 30 Following treatment of the products with protease K, urea is added and analysis on 20% polyacrylamide gels containing urea is done. Gel products are visualized by staining with Stains All reagent (Sigma Chemical Co.). Laser densitometry is used to quantitate the extent of 35 degradation. The effects of the modified linkage are

- 71 -

determined for specific nucleases and compared with the results obtained from the serum and cytoplasmic systems. As with the serum and cytoplasmic nucleases, it is expected that the oligonucleotide surrogates of the invention will be completely resistant to endo- and exo-nucleases.

PROCEDURE 3 - 5-Lipoxygenase Analysis, Therapeutics and Assays

A. Therapeutics

10 For therapeutic use, an animal suspected of having a disease characterized by excessive or abnormal supply of 5-lipoxygenase is treated by administering oligo-nucleotide surrogates of the invention. Persons of ordinary skill can easily determine optimum dosages, 15 dosing methodologies and repetition rates. Such treatment is generally continued until either a cure is effected or a diminution in the diseased state is achieved. Long term treatment is likely for some diseases.

B. Research Reagents

20 The oligonucleotide surrogates of this invention will also be useful as research reagents when used to cleave or otherwise modulate 5-lipoxygenase mRNA in crude cell lysates or in partially purified or wholly purified RNA preparations. This application of the invention is 25 accomplished, for example, by lysing cells by standard methods, optimally extracting the RNA and then treating it with a composition at concentrations ranging, for instance, from about 100 to about 500 ng per 10 Mg of total RNA in a buffer consisting, for example, of 50 mm 30 phosphate, pH ranging from about 4-10 at a temperature from about 30° to about 50° C. The cleaved 5-lipoxygenase RNA can be analyzed by agarose gel electrophoresis and hybridization with radiolabeled DNA probes or by other standard methods.

GP 056001

SUBSTITUTE SHEET

C. Diagnostics

The oligonucleotide surrogates of this invention will also be useful in diagnostic applications, particularly for the determination of the expression of specific mRNA species in various tissues or the expression of abnormal or mutant RNA species. In this example, the oligonucleotide surrogates target a hypothetical abnormal mRNA by being designed complementary to the abnormal sequence, but would not hybridize to normal mRNA.

10 Tissue samples can be homogenized, and RNA extracted by standard methods. The crude homogenate or extract can be treated for example to effect cleavage of the target RNA. The product can then be hybridized to a solid support which contains a bound oligonucleotide complementary to a region on the 5' side of the cleavage site. Both the normal and abnormal 5' region of the mRNA would bind to the solid support. The 3' region of the abnormal RNA, which is cleaved, would not be bound to the support and therefore would be separated from the normal mRNA.

20 Targeted mRNA species for modulation relates to 5-lipoxygenase; however, persons of ordinary skill in the art will appreciate that the present invention is not so limited and it is generally applicable. The inhibition or modulation of production of the enzyme 5-lipoxygenase is expected to have significant therapeutic benefits in the treatment of disease. In order to assess the effectiveness of the compositions, an assay or series of assays is required.

D. In Vitro Assays

30 The cellular assays for 5-lipoxygenase preferably use the human promyelocytic leukemia cell line HL-60. These cells can be induced to differentiate into either a monocyte-like cell or neutrophil-like cell by various known agents. Treatment of the cells with 1.3% dimethyl sulfoxide, DMSO, is known to promote differentiation of

35

the cells into neutrophils. It has now been found that basal HL-60 cells do not synthesize detectable levels of 5-lipoxygenase protein or secrete leukotrienes (a downstream product of 5-lipoxygenase). Differentiation of the
5 cells with DMSO causes an appearance of 5-lipoxygenase protein and leukotriene biosynthesis 48 hours after addition of DMSO. Thus induction of 5-lipoxygenase protein synthesis can be utilized as a test system for analysis of antisense oligonucleotides surrogates which
10 interfere with 5-lipoxygenase synthesis in these cells.

A second test system for antisense oligonucleotides surrogates makes use of the fact that 5-lipoxygenase is a "suicide" enzyme in that it inactivates itself upon reacting with substrate. Treatment of differentiated HL-
15 60 or other cells expressing 5 lipoxygenase, with 10 μ M A23187, a calcium ionophore, promotes translocation of 5-lipoxygenase from the cytosol to the membrane with subsequent activation of the enzyme. Following activation and several rounds of catalysis, the enzyme becomes
20 catalytically inactive. Thus, treatment of the cells with calcium ionophore inactivates endogenous 5-lipoxygenase. It takes the cells approximately 24 hours to recover from A23187 treatment as measured by their ability to synthesize leukotriene B₄. Oligonucleotide surrogates directed
25 against 5-lipoxygenase can be tested for activity in two HL-60 model systems using the following quantitative assays. The assays are described from the most direct measurement of inhibition of 5-lipoxygenase protein synthesis in intact cells to more downstream events such
30 as measurement of 5-lipoxygenase activity in intact cells.

The most direct effect which oligonucleotide surrogates can exert on intact cells and which can be easily be quantitated is specific inhibition of 5-lipoxygenase protein synthesis. To perform this technique, cells can

- 74 -

be labelled with ^{25}S -methionine (50 $\mu\text{Ci}/\text{mL}$) for 2 hours at 37° C to label newly synthesized protein. Cells are extracted to solubilize total cellular proteins and 5-lipoxygenase is immunoprecipitated with 5-lipoxygenase antibody followed by elution from protein A Sepharose beads. The immunoprecipitated proteins are resolved by SDS-polyacrylamide gel electrophoresis and exposed for autoradiography. The amount of immunoprecipitated 5-lipoxygenase is quantitated by scanning densitometry.

10 A predicted result from these experiments would be as follows. The amount of 5-lipoxygenase protein immunoprecipitated from control cells would be normalized to 100%. Treatment of the cells with 1 μM , 10 μM , and 30 μM of effective oligonucleotide surrogates for 48 hours would
15 reduce immunoprecipitated 5-lipoxygenase by 5%, 25% and 75% of control, respectively.

Measurement of 5-lipoxygenase enzyme activity in cellular homogenates could also be used to quantitate the amount of enzyme present which is capable of synthesizing
20 leukotrienes. A radiometric assay has now been developed for quantitating 5-lipoxygenase enzyme activity in cell homogenates using reverse phase HPLC. Cells are broken by sonication in a buffer containing protease inhibitors and EDTA. The cell homogenate is centrifuged at 10,000
25 x g for 30 min and the supernatants analyzed for 5-lipoxygenase activity. Cytosolic proteins are incubated with 10 μM ^{14}C -arachidonic acid, 2mM ATP, 50 μM free calcium, 100 $\mu\text{g}/\text{ml}$ phosphatidylcholine, and 50 mM bis-Tris buffer, pH 7.0, for 5 min at 37° C. The reactions
30 are quenched by the addition of an equal volume of acetone and the fatty acids extracted with ethyl acetate. The substrate and reaction products are separated by reverse phase HPLC on a Novapak C18 column (Waters Inc., Millford, MA). Radioactive peaks are detected by a Beckman model

GP 056004

SUBSTITUTE SHEET

- 75 -

171 radiochromatography detector. The amount of arachidonic acid converted into di-HETE's and mono-HETE's is used as a measure of 5-lipoxygenase activity.

A predicted result for treatment of DMSO differentiated HL-60 cells for 72 hours with effective oligonucleotide surrogates at 1 μ M, 10 μ M, and 30 μ M would be as follows. Control cells oxidize 200 pmol arachidonic acid/ 5 min/ 10^6 cells. Cells treated with 1 μ M, 10 μ M, and 30 μ M of an effective oligonucleotide surrogates would oxidize 195 pmol, 140 pmol, and 60 pmol of arachidonic acid/ 5 min/ 10^6 cells respectively.

A quantitative competitive enzyme linked immunosorbant assay (ELISA) for the measurement of total 5-lipoxygenase protein in cells has been developed. Human 5-lipoxygenase expressed in E. coli and purified by extraction, Q-Sepharose, hydroxyapatite, and reverse phase HPLC is used as a standard and as the primary antigen to coat microtiter plates. 25 ng of purified 5-lipoxygenase is bound to the microtiter plates overnight at 4° C. The wells are blocked for 90 min with 5% goat serum diluted in 20 mM Tris•HCL buffer, pH 7.4, in the presence of 150 mM NaCl (TBS). Cell extracts (0.2% Triton X-100, 12,000 x g for 30 min.) or purified 5-lipoxygenase were incubated with a 1:4000 dilution of 5-lipoxygenase polyclonal antibody in a total volume of 100 μ L in the microtiter wells for 90 min. The antibodies are prepared by immunizing rabbits with purified human recombinant 5-lipoxygenase. The wells are washed with TBS containing 0.05% tween 20 (TEST), then incubated with 100 μ L of a 1:1000 dilution of peroxidase conjugated goat anti-rabbit IgG (Cappel Laboratories, Malvern, PA) for 60 min at 25° C. The wells are washed with TEST and the amount of peroxidase labelled second antibody determined by development with tetramethylbenzidine.

GP 056005

SUBSTITUTE SHEET

- 76 -

Predicted results from such an assay using a 30 mer oligonucleotide analog at 1 μM , 10 μM , and 30 μM would be 30 ng, 18 ng and 5 ng of 5-lipoxygenase per 10^5 cells, respectively with untreated cells containing about 34 ng 5-lipoxygenase.

A net effect of inhibition of 5-lipoxygenase biosynthesis is a diminution in the quantities of leukotrienes released from stimulated cells. DMSO-differentiated HL-60 cells release leukotriene B4 upon stimulation with the calcium ionophore A23187. Leukotriene B4 released into the cell medium can be quantitated by radioimmuncassay using commercially available diagnostic kits (New England Nuclear, Boston, MA). Leukotriene B4 production can be detected in HL-60 cells 48 hours following addition of DMSO to differentiate the cells into a neutrophil-like cell. Cells (2×10^5 cells/mL) will be treated with increasing concentrations of oligonucleotide surrogates for 48-72 hours in the presence of 1.3 % DMSO. The cells are washed and resuspended at a concentration of 2×10^6 cell/mL in Dulbecco's phosphate buffered saline containing 1% delipidated bovine serum albumin. Cells are stimulated with 10 μM calcium ionophore A23187 for 15 min and the quantity of LTB4 produced from 5×10^5 cell determined by radioimmunoassay as described by the manufacturer.

Using this assay the following results would likely be obtained with a 15-mer oligonucleotide surrogate of the sequence (GCAAGGTCCTGAAG) directed to the 5-LO mRNA. Cells will be treated for 72 hours with either 1 μM , 10 μM or 30 μM oligonucleotide surrogate in the presence of 1.3% DMSO. The quantity of LTB₄ produced from 5×10^5 cells would be expected to be about 75 pg, 50 pg, and 35 pg, respectively with untreated differentiated cells producing 75 pg LTB₄.

GP 056006

SUBSTITUTE SHEET

- 77 -

E. In Vivo Assay

Inhibition of the production of 5-lipoxygenase in the mouse can be demonstrated in accordance with the following protocol. Topical application of arachidonic acid results in the rapid production of leukotriene B₄, leukotriene C₄ and prostaglandin E₂ in the skin followed by edema and cellular infiltration. Certain inhibitors of 5-lipoxygenase have been known to exhibit activity in this assay. For the assay, 2 mg of arachidonic acid is applied to a mouse ear with the contralateral ear serving as a control. The polymorphonuclear cell infiltrate is assayed by myeloperoxidase activity in homogenates taken from a biopsy 1 hour following the administration of arachidonic acid. The edematous response is quantitated by measurement of ear thickness and wet weight of a punch biopsy. Measurement of leukotriene B₄ produced in biopsy specimens is performed as a direct measurement of 5-lipoxygenase activity in the tissue. Oligonucleotide surrogates will be applied topically to both ears 12 to 24 hours prior to administration of arachidonic acid to allow optimal activity of the compounds. Both ears are pretreated for 24 hours with either 0.1 μmol, 0.3 μmol, or 1.0 μmol of the oligonucleotide analog prior to challenge with arachidonic acid. Values are expressed as the mean for three animals per concentration. Inhibition of polymorphonuclear cell infiltration for 0.1 μmol, 0.3 μmol, and 1 μmol is expected to be about 10 %, 75 % and 92 % of control activity, respectively. Inhibition of edema is expected to be about 3 %, 58% and 90%, respectively while inhibition of leukotriene B₄ production would be expected to be about 15 %, 79% and 99%, respectively.

GP 056007

SUBSTITUTE SHEET

- 78 -

PROCEDURE 4 - ANTIVIRAL ACTIVITY

Certain of the heterocyclic base substituted cyclobutane compound of the invention were tested as to their antiviral activity. Both 1-adenyl-3,3-bis-hydroxymethyl-cyclobutane and 1-thymindyl-3,3-bis-hydroxymethyl-cyclobutane were tested against HSV-1 in human macrophages. Both of these compounds were tested up to 600 μ g/ml without toxicity. In these tests 1-thymindyl-3,3-bis-hydroxymethyl-cyclobutane exhibited a MED₅₀ of 40 - 65 μ g/ml and 1-adenyl-3,3-bis-hydroxymethyl-cyclobutane exhibited a MED₅₀ of 200 μ g/ml. Both of these compounds showed no activity in a cellular HIV assay.


GP 056008

SUBSTITUTE SHEET

WE CLAIM:

1. An oligonucleotide surrogate comprising a plurality of cyclobutyl moieties covalently joined by linking moieties, wherein each of said cyclobutyl moieties include an attached purine or an attached pyrimidine heterocyclic base.
2. An oligonucleotide surrogate of claim 1 wherein said purine or pyrimidine heterocyclic base is a naturally-occurring or synthetic purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl heterocyclic base.
3. An oligonucleotide surrogate of claim 2 wherein said purine or pyrimidine heterocyclic base is adenine, guanine, cytosine, thymidine, uracil, 5-methylcytosine, hypoxanthine or 2-aminoadenine.
4. An oligonucleotide surrogate of claim 1 wherein said heterocyclic base is attached to each respective cyclobutyl moiety at a C-1 position of said cyclobutyl moiety.
5. An oligonucleotide surrogate of claim 4 wherein each of said linking moieties connects to two of the cyclobutyl moieties at a C-3 position of the cyclobutyl moieties.
6. An oligonucleotide surrogate of claim 1 wherein each of said linking moieties comprises a 4 atom or a 5 atom chain that joins two of the cyclobutyl moieties.
7. An oligonucleotide surrogate of claim 6 wherein each of said linking moieties comprises a 5 atom chain that joins two of the cyclobutyl moieties.


8. An oligonucleotide surrogate of claim 7 wherein each of said linking moieties is of the structure:



where:

L_1 and L_3 are CH_2 ; and
 L_2 is phosphodiester, phosphorothioate, phosphoramidate, phosphotriester, C_1-C_6 alkyl phosphonate, phosphorodithioate, phosphonate, carbamate, sulfonate, C_1-C_6 -dialkylsilyl or formacetal.

9. An oligonucleotide surrogate of claim 7 wherein each of said linking moieties is of the structure:




where:

L_1 and L_3 are CH_2 ; and
 L_2 is phosphodiester or phosphorothioate.

10. An oligonucleotide surrogate of claim 6 wherein each of said linking moieties comprises a 4 atom chain that joins two of the cyclobutyl moieties.

11. An oligonucleotide surrogate of claim 10 wherein each of said linking moieties is of the structure:



where:

- (a) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , independently, are CR_1R_2 , $C=CR_1R_2$, $C=NR_2$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_4R_5 ;
or
(b) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , together, are $CR_1=CR_2$, $C\equiv C$, part of a C_6 aromatic ring, part of a C_3-C_6 carbocyclic

- 81 -

ring or part of a 3, 4, 5 or 6 membered heterocyclic ring; or

(c) $L_4-L_5-L_6-L_7$, together, are $CH=N-NH-CH_2$ or $CH_2-O-N=CH$;

where:

R_1 and R_2 , independently, are H, OH, SH, NH_2 , C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_1-C_{10} alkenyl, C_7-C_{10} aralkyl, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, C_1-C_6 alkylamino, C_7-C_{10} aralkylamino, C_1-C_{10} substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, halo, formyl, keto, benzoxy, carboxamido, thiocarboxamido, ester, thioester, carboxamidino, carbamyl, ureido, guanidino, an RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide;

R_3 is H, OH, NH_2 , C_1-C_6 alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, a RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; and

R_4 and R_5 , independently, are C_1-C_6 alkyl or alkoxy.

12. An oligonucleotide surrogate compound of claim 10 wherein each of said linking moieties is $CH=N-NH-CH_2$, $CH_2-NH-NH-CH_2$, $CH_2-O-NH-CH_2$ or $CH_2-O-N=CH$.

13. An oligonucleotide surrogate of claim 5 further including a substituent group attached to at least one of the cyclobutyl moieties at a C-2 position or a C-4 position of the cyclobutyl moieties.

14. An oligonucleotide surrogate of claim 13 wherein said substituent group is halogen, C₁-C₁₀ alkoxy, allyloxy, C₁-C₁₀ alkyl or C₁-C₁₀ alkylamine.

15. An oligonucleotide surrogate of claim 14 wherein said substituent group is positioned trans to said heterocyclic base.

16. An oligonucleotide surrogate comprising:
a plurality of cyclobutyl moieties which individually include a purine or a pyrimidine heterocyclic base attached to a C-1 position of each cyclobutyl moiety; and
a plurality of linking moieties which include a 4 atom or a 5 atom chain and which join two adjacent cyclobutyl moieties at a C-3 position of the cyclobutyl moieties.

17. A method for modulating the production or activity of a protein in an organism, comprising contacting the organism with an oligonucleotide surrogate formed from a plurality of cyclobutyl moieties covalently joined by linking moieties, wherein each of said cyclobutyl moieties includes an attached purine or an attached pyrimidine heterocyclic base.


18. The method of claim 17 wherein said purine or pyrimidine heterocyclic base is a naturally-occurring or synthetic purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl heterocyclic base.

19. The method of claim 17 wherein:
 said heterocyclic base is attached to each respective cyclobutyl moiety at a C-1 position of said cyclobutyl moiety; and

each of said linking moieties connects to two of the cyclobutyl moieties at a C-3 position of the cyclobutyl moieties.

20. The method of claim 17 wherein each of said linking moieties comprises a 4 atom or a 5 atom chain that joins two of the cyclobutyl moieties.

21. The method oligonucleotide of claim 20 wherein each of said linking moieties is of the structure




where:

L_1 and L_3 are CH_2 ; and

L_2 is phosphodiester, phosphorothioate, phosphoramidate, phosphotriester, C_1-C_6 alkyl phosphonate, phosphorodithioate, phosphonate, carbamate, sulfonate, C_1-C_6 -dialkylsilyl or formacetal.

22. The method of claim 20 wherein each of said linking moieties is of the structure:



where:

(a) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , independently, are CR_1R_2 , $C=CR_1R_2$, $C=NR_3$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_4R_5 ;
 or

(b) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , together, are $CR_1=CR_2$, $C=C$, part of a C_6 aromatic ring, part of a C_3-C_6 carbocyclic

ring or part of a 3, 4, 5 or 6 membered heterocyclic ring; or

- (c) $L_4-L_5-L_6-L_7$, together, are $CH=N-NH-CH_2$ or $CH_2-O-N=CH$;

where:

R_1 and R_2 , independently, are H, OH, SH, NH_2 , C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_1-C_{10} alkenyl, C_7-C_{10} aralkyl, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, C_1-C_6 alkylamino, C_7-C_{10} aralkylamino, C_1-C_{10} substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, halo, formyl, keto, benzoxy, carboxamido, thiocarboxamido, ester, thioester, carboxamidino, carbamyl, ureido, guanidino, an RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide;

R_3 is H, OH, NH_2 , C_1-C_6 alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, a RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; and

R_4 and R_5 , independently, are C_1-C_6 alkyl or alkoxy.

23. The method of claim 20 wherein each of said linking moieties is $CH=N-NH-CH_2$, $CH_2-NH-NH-CH_2$, $CH_2-O-NH-CH_2$ or $CH_2-O-N=CH$.

24. The method of claim 20 wherein:

said purine or pyrimidine heterocyclic base is adenine, guanine, cytosine, thymidine, uracil, 5-methylcytosine, hypoxanthine or 2-aminoadenine;

- 85 -

said heterocyclic base is attached to each respective cyclobutyl moiety at a C-1 position of said cyclobutyl moiety; and

each of said linking moieties connects to two of the cyclobutyl moieties at a C-3 position of the cyclobutyl moieties.

25. A method of treating an organism having a disease characterized by the undesired production of a protein, comprising contacting the organism with an oligonucleotide surrogate formed from a plurality of cyclobutyl moieties covalently joined by linking moieties, each of said cyclobutyl moieties includes an attached purine or an attached pyrimidine heterocyclic base.

26. The method of claim 25 wherein said purine or pyrimidine heterocyclic base is a naturally-occurring or synthetic purin-9-yl, pyrimidin-1-yl or pyrimidin-3-yl heterocyclic base.

27. The method of claim 25 wherein:

said heterocyclic base is attached to each respective cyclobutyl moiety at a C-1 position of said cyclobutyl moiety; and

each of said linking moieties connects to two of the cyclobutyl moieties at a C-3 position of the cyclobutyl moieties.


28. The method of claim 25 wherein each of said linking moieties comprises a 4 atom or a 5 atom chain that joins two of the cyclobutyl moieties.

29. The method oligonucleotide of claim 28 wherein each of said linking moieties is of the structure

GP 056015

SUBSTITUTE SHEET


- 86 -



where:

L_1 and L_3 are CH_2 ; and
 L_2 is phosphodiester, phosphorothioate, phosphoramidate, phosphotriester, C_1-C_6 alkyl phosphonate, phosphorodithioate, phosphonate, carbamate, sulfonate, C_1-C_6 -dialkylsilyl or formacetal.

30. The method of claim 28 wherein each of said linking moieties is of the structure:



where:

- (a) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , independently, are CR_1R_2 , $C=CR_1R_2$, $C=NR_3$, $C=O$, $C=S$, O , S , SO , SO_2 , NR_3 or SiR_4R_5 ;
or
(b) L_4 and L_7 are CH_2 ; and
 L_5 and L_6 , together, are $CR_1=CR_2$, $C\equiv C$, part of a C_6 aromatic ring, part of a C_3-C_6 carbocyclic ring or part of a 3, 4, 5 or 6 membered heterocyclic ring; or
(c) $L_4-L_5-L_6-L_7$, together, are $CH=N-NH-CH_2$ or $CH_2-O-N=CH$;

where:

R_1 and R_2 , independently, are H, OH, SH, NH_2 , C_1-C_{10} alkyl, C_1-C_{10} substituted alkyl, C_1-C_{10} alkenyl, C_7-C_{10} aralkyl, C_1-C_6 alkoxy, C_1-C_6 thioalkoxy, C_1-C_6 alkylamino, C_7-C_{10} aralkylamino, C_1-C_{10} substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, halo, formyl, keto, benzoxy, carboxamido, thiocarboxamido, ester, thioester, carboxamidino, carbamyl, ureido, guanidino, an RNA cleaving group, a group for improving the pharmacokinetic properties of an oligo-

GP 056016

- 87 -

nucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide;

R_3 is H, OH, NH_2 , C_1-C_6 alkyl, substituted lower alkyl, alkoxy, lower alkenyl, aralkyl, alkylamino, aralkylamino, substituted alkylamino, heterocycloalkyl, heterocycloalkylamino, aminoalkylamino, polyalkylamino, a RNA cleaving group, a group for improving the pharmacokinetic properties of an oligonucleotide and a group for improving the pharmacodynamic properties of an oligonucleotide; and

R_4 and R_5 , independently, are C_1-C_6 alkyl or alkoxy.

31. The method of claim 28 wherein each of said linking moieties is $CH=N-NH-CH_2$, $CH_2-NH-NH-CH_2$, $CH_2-O-NH-CH_2$ or $CH_2-O-N=CH$.

32. The method of claim 28 wherein:

said purine or pyrimidine heterocyclic base is adenine, guanine, cytosine, thymidine, uracil, 5-methylcytosine, hypoxanthine or 2-aminoadenine;

said heterocyclic base is attached to each respective cyclobutyl moiety at a C-1 position of said cyclobutyl moiety; and

each of said linking moieties connects to two of the cyclobutyl moieties at a C-3 position thereof.

33. A composition comprising:

a pharmaceutically effective amount of a compound formed from a plurality of cyclobutyl moieties covalently joined by linking moieties, wherein each of said cyclobutyl moieties includes an attached purine or an attached pyrimidine heterocyclic base; and

a pharmaceutically acceptable diluent or carrier.

GP 056017

SUBSTITUTE SHEET

- 88 -

34. A method of in vitro assaying a sequence-specific nucleic acid, comprising contacting a test solution containing said nucleic acid with an oligonucleotide surrogate compound formed from a plurality of cyclobutyl moieties covalently joined by linking moieties, wherein each of said cyclobutyl moieties includes an attached purine or an attached pyrimidine heterocyclic base.

35. A process for the preparation of a compound formed from a plurality of cyclobutyl moieties covalently joined by linking moieties, wherein each of said cyclobutyl moieties includes an attached purine or an attached pyrimidine heterocyclic base, said process comprising the steps of:

functionalizing cyclobutyl moieties with a leaving group;

displacing said leaving group on each of said cyclobutyl moieties with an independently selected purine or pyrimidine heterocyclic base;

functionalizing each of said heterocyclic-base-containing cyclobutyl moieties with a protecting group;

functionalizing said protected moieties with an activated linking group; and

stepwise deprotecting and linking said protected, activated moieties.

36. The process of claim 35 wherein said protected, activated moieties are deprotected and linked on a polymeric support.

37. The process of claim 35 wherein said protected, activated moieties are deprotected and linked by a process which includes:

GP 056018

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01579

A. CLASSIFICATION OF SUBJECT MATTER IPC(5) : A61K 48/00; C07H 21/00, 21/04; C12Q 1/68 US CL : 536/24.5, 25.3; 514/44; 435/6 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/24.5, 25.3, 25.6 ; 514/44; 435/6; 935/34, 44, '62																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA, BIOSIS, MEDLINE, APS																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	ANGEWANDTE, Volume 31, No. 4, issued 31 April 1992, J-M Henlin et al., "Synthesis of OCTomeric Phosphodiester of [3,3-Bis(hydroxymethyl)cyclobutyl]adenine and -Thymine as well as their Hybridization Properties", pages 482-484, see entire document.	1-37																		
Y	HELVETICA CHIMICA ACTA, Volume 75, issued 18 March 1992, J-M Henlin et al. "Synthesis of 3-Adenyl- and 3-Thiminylcyclobutane-1,1-dimethanols and Their Homo-octameric Phosphodiester", pages 589-603, see entire document.	1-37																		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be part of particular relevance</td> <td>*X*</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y*</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z*</td> <td>document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means			*P* document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family																		
O document referring to an oral disclosure, use, exhibition or other means																				
P document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 29 April 1993	Date of mailing of the international search report 12 NOV 1993																			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer PAUL B. TRAN, PH.D. <i>P. B. Tran</i>																			
Facsimile No. NOT APPLICABLE	Telephone No. (703) 308-0196																			

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01579

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,087,617 (Smith) 11 FEBRUARY 1992, see entire document.	17-32

INTERNATIONAL SEARCH REPORT

Int. national application No.

PCT/US93/01579

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(Telephone Practice)

- I. Claims 1-24, 33, 35-37, drawn to an oligonucleotide surrogate or a composition thereof, methods to modulate an activity of a protein in an organism, methods to make a surrogate compound, classified in Class 536, subclass 25.3, 24.5; Class 514, subclass 44.
- II. Claims 25-32, drawn to methods of treating disease using an oligonucleotide surrogate, classified in Class 514, subclass 44.
- III. Claim 34, drawn to method to assay in vitro a sequence-specific nucleic acid, classified in Class 435, subclass 6.

Under PCT Rule 13.2(i), claims are permitted to one product, one process of manufacturing and one use. The claims in the present application are drawn to more than one methods of use, namely, methods of modulating an activity of a protein in an organism (claims 17-24 of Group I), methods of treating disease (claims 25-32 of Group II), and a method of in vitro assaying sequence-specific nucleic acid (claim 34 of Group III).

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.